Document:

<PAGE>

                              AMENDED AND RESTATED
                          LICENSE AND SUPPLY AGREEMENT

         This Amended and Restated License and Supply Agreement (this
"AGREEMENT"), dated and effective as of November 3, 1999 (the "EFFECTIVE DATE"),
is by and between SENETEK PLC, a British public company ("SENETEK"), with an
office at 620 Airpark Road, Napa, California 94588, and OBAGI MEDICAL PRODUCTS,
INC., a California corporation ("OBAGI"), with an office at 310 Golden Shore,
Long Beach, California 90802. This Agreement amends and restates in its entirety
that certain License and Supply Agreement, dated as of November 1, 1999, by and
between the parties hereto.

                                    RECITALS:

         A. Obagi wishes to purchase from Senetek, and to acquire a license to
market, distribute and sell, (i) 0.05% kinetin cream and lotion and SPF
("PRODUCT A"), and (ii) 0.05% kinetin with a fruit acid (including, without
limitation, phytic or glycolic acids) ("PRODUCT B"), in each case pursuant to
the terms and conditions set forth herein.

         B. Senetek is willing to sell to Obagi, and to grant a license to Obagi
to market, distribute and sell, Product A and Product B pursuant to the terms
and conditions set forth herein.

         NOW, THEREFORE, in consideration of the premises and the mutual
covenants and undertakings set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

         1.1 The Preamble and Recitals hereto are intended to be an integral
part of this Agreement, and the Preamble and Recitals hereto (including the
definitions set forth therein) are hereby incorporated by reference.

         1.2 As used in this Agreement, the following capitalized terms shall
have the following respective meanings:

         "ACTUAL DIRECT NET COST" shall mean, as to any Unit, the amount equal
to the sum of (a) the amount invoiced to Senetek by its manufacturer for
production of such Unit including, without limitation, the cost of any packaging
or labeling (net of any discounts and credits on account of the purchase of such
Unit), PLUS (b) the portion of Senetek's direct manufacturing support costs
directly related to the production of the Products, allocated ratably among all

<PAGE>

individual packaged units of Products to which such costs relate, but excluding
the shipping and delivery charges of finished products from the manufacturer to
Obagi.

         "AFFILIATE" shall mean (a) any company owned or controlled to the
extent of at least fifty percent (50%) of its issued and voting capital
securities by a party to this Agreement and any other company so owned or
controlled (directly or indirectly) by any such company or the owner of any such
company, or (b) any partnership, joint venture or other entity directly or
indirectly controlled by, controlling, or under common control of, to the extent
of fifty percent (50%) or more of voting power (or otherwise having power to
control its general activities) by a party to this Agreement, but in each case
only for so long as such ownership or control shall continue.

         "CAMBODIA" shall mean the Kingdom of Cambodia and any successor(s)
thereto, including its territories and possessions.

         "CHINA" shall mean the People's Republic of China and any successor(s)
thereto, including its territories and possessions, but excluding Hong Kong.

         "CONTRACT YEAR" shall mean a period from April 1 of a calendar year
through March 31 of the next following calendar year; PROVIDED that the first
Contract Year shall commence on the Effective Date and continue through March
31, 2001.

         "DOLLAR", "DOLLARS" or "$" shall mean the legal currency of the United
States of America.

         "HONG KONG" shall mean the area currently constituting the Hong Kong
Special Administrative Region of China.

         "IMPROVEMENT" means any information, discovery, creation, derivative
work, invention, or trade secret, whether or not patented or patentable or
copyrighted or copyrightable, that relates to or is based upon the Intellectual
Property and is developed or otherwise acquired by either party, their
Affiliates or any of their respective employees, officers or agents.

          "INDEMNIFIABLE DAMAGES" shall mean the sum of (i) all losses, claims,
damages, liabilities, costs, expenses or deficiencies described in Article VII,
PLUS (ii) an amount of interest on the amount in clause (i) (computed before the
application of this clause (ii)) computed at the rate of eight and one-half
percent (8.5%) per annum from the date notice of such claim for Indemnifiable
Damages was given to the Indemnifying Party by the Indemnified Party hereunder
until paid by the Indemnifying Party hereunder.

         "INITIAL TERM" shall mean the period commencing on the Effective Date
and concluding (unless earlier terminated pursuant to the terms herein) on the
tenth anniversary of the Effective Date.

         "INTELLECTUAL PROPERTY" shall mean (i) patents and patent applications,
(ii) trademarks, trade names, service marks and registrations and applications
for registrations thereof (including,

                                       2
<PAGE>

but not limited to, "kinetin" and analogs thereof), (iii) copyrights and
copyright registrations, (iv) trade secrets and secret processes, and (v) other
Know-How, in each case relating to the Products (or any Product) and in the
United States of America and each Territory.

         "JAPAN" shall mean Japan and any successor(s) thereto, including its
territories and possessions.

         "KNOW-HOW" shall mean such know-how, special knowledge, data, studies,
technical or other information, whether or not patented or patentable, owned or
controlled by Senetek at any time prior to or during the Term specifically
related to the development, manufacture or use of the Product.

         "MALAYSIA" shall mean Malaysia and any successor(s) thereto, including
its territories and possessions.

         "MARKET" shall mean (a) the mass market in all Territories other than
Taiwan and (b) multi-level markets in the case of Taiwan.

         "NET SALES" shall mean net sales as determined in accordance with
United States generally accepted accounting principles applied consistently
throughout the relevant periods.

         "OBAGI CONFIDENTIAL INFORMATION" means marketing, sales, financial,
scientific, and other non-public and/or proprietary information concerning the
products, projects, business and operations of Obagi including the manufacture,
use, or sale of the Products disclosed by Obagi to Senetek; PROVIDED, HOWEVER,
that Obagi Confidential Information shall not include any of the following: (i)
information which becomes known to Senetek on a non-confidential basis from a
source other than Obagi, provided that such source is not known by Senetek to be
prohibited from disclosing such information by a contractual, fiduciary or other
obligation owed to Obagi; (ii) information independently developed by Senetek
without the use of any of the information received from Obagi; or (iii)
information which has become generally known to the public other than as a
result of Senetek's breach of this Agreement.

         "PATENT TERMINATION DATE" shall mean, as to any Product in any
Territory, the date on which any patent relating to any Product shall expire or
otherwise cease to be valid in such Territory.

          "PHILIPPINES" or "THE PHILIPPINES" shall mean the Republic of the
Philippines and any successor(s) thereto, including its territories and
possessions.

         "PRIMARY TERRITORIES" shall mean, collectively, China, Japan,
Philippines, Taiwan, South Korea and Malaysia, and each is a Primary Territory.

         "PRODUCTS" or "PRODUCT" shall mean, individually or collectively, any
or all of Product A and Product B. Upon the granting of any licenses and rights
as contemplated by Sections 2.4 and

                                       3
<PAGE>

2.5 hereof and the amendment of this Agreement pursuant to Section 2.6, such
additional products for which such license is granted shall thereafter also be
deemed Products.

         "RENEWAL TERM" shall mean a period commencing on the last day of the
Initial Term or the then-expiring Renewal Term, as the case may be, and
concluding on the third anniversary thereof as may be agreed to by the parties
prior to the expiration of the Term; PROVIDED, HOWEVER, in the event that any
patent licensed hereunder terminates during the Renewal Term, this Agreement
shall terminate solely with respect to the Product and Territory to which such
patent relates as of the Patent Termination Date, and the parties shall adjust
the Minimum Purchase Requirement in accordance with Section 4.2.

         "SECONDARY TERRITORIES" shall mean, collectively, all Territories other
than Primary Territories, and each is a "Secondary Territory."

         "SENETEK CONFIDENTIAL INFORMATION" means marketing, sales, financial,
scientific, and other non-public and/or proprietary information concerning the
products, projects, business and operations of Senetek including the
manufacture, use, or sale of the Products disclosed by Senetek to Obagi;
PROVIDED, HOWEVER, that Senetek Confidential Information shall not include any
of the following: (i) information which becomes known to Obagi on a
non-confidential basis from a source other than Senetek, provided that such
source is not known by Obagi to be prohibited from disclosing such information
by a contractual, fiduciary or other obligation owed to Senetek; (ii)
information independently developed by Obagi without the use of any of the
information received from Senetek; or (iii) information which has become
generally known to the public other than as a result of Obagi's breach of this
Agreement.

         "SINGAPORE" shall mean the Republic of Singapore and any successor(s)
thereto, including its territories and possessions.

         "SOUTH KOREA" shall mean the Republic of Korea and any successor(s)
thereto, including its territories and possessions.

         "TAIWAN" shall mean the Republic of China (also known as Taiwan) and
any successor(s) thereto, including its territories and possessions.

         "TARGET LAUNCH DATE" shall mean (a) December 31, 1999 in the case of
Taiwan and (b) June 30, 2000 in the case of Singapore, Hong Kong and Japan.

         "TERM" shall mean, collectively, the Initial Term and any Renewal
Term(s); provided, however, in the event this Agreement is terminated in
accordance with Article X hereof, the Term shall end as of the date this
Agreement is terminated.

         "TERRITORIES" shall mean, collectively, Cambodia, China, Hong Kong,
Japan, Malaysia, South Korea, Philippines, Singapore, Taiwan and Vietnam, and
each is a "TERRITORY".

                                       4
<PAGE>

         "UNIT" shall mean an individual unit of Product packaged in accordance
with specifications provided by Obagi from time to time and reasonably
acceptable to Senetek.

         "VIETNAM" shall mean the Socialist Republic of Vietnam and any
successor(s) thereto, including its territories and possessions.

                                   ARTICLE II
                           PURCHASE, SALE AND LICENSE

         2.1 During the Term, Senetek agrees to supply and deliver to Obagi, and
Obagi agrees to purchase from Senetek, Products in such quantities as Obagi
requests. All orders for Products shall be made pursuant to written purchase
orders or binding forecasts delivered to Senetek in accordance with Article IV
hereof.

         2.2 Senetek hereby grants to Obagi the exclusive license and right to
market, distribute and sell the Products in the Territories and, in each
Territory, solely within the Market for such Territory; PROVIDED, HOWEVER, that
if Obagi fails to launch marketing and distribution efforts in China on or
before November 1, 2001, such exclusive license and rights as to China shall
automatically revert to Senetek and Obagi will have no further rights with
respect to the Products in China; PROVIDED, FURTHER, that if Obagi fails to
launch marketing and distribution efforts in South Korea on or before November
1, 2001, such exclusive license and rights as to South Korea shall automatically
revert to Senetek and Obagi will have no further rights with respect to the
Products in South Korea; PROVIDED, FURTHER, that in the event that during any
Contract Year during the Term Obagi fails to purchase an aggregate number of
Units equal to or greater than the Minimum Purchase Requirement, in addition to
any rights to terminate this Agreement pursuant to Article X, such license as is
granted pursuant to this Section 2.2 shall cease to be exclusive, and Senetek
shall be permitted to license and sell the Products to other persons or entities
for resale in all or any part of the Territory or the Market.

         2.3      [Intentionally Omitted.]

         2.4 Senetek hereby grants Obagi a right of first offer to obtain
exclusive licenses and rights to market, distribute and sell any and all new
kinetin products, products containing kinetin, and kinetin analogs (including,
without limitation, Zeatin and analogs thereof) or any Improvements relating to
any of the foregoing in the Territories. Senetek shall give Obagi written notice
prior to making any such new product available for distribution and sale. During
the sixty (60) day period following Obagi's receipt of such written notice,
Obagi may deliver an offer to Senetek setting forth an offer to purchase,
market, distribute and/or sell such new product. If Obagi makes any such offer,
Senetek and Obagi shall negotiate in good faith toward reaching a formal
agreement through the remainder of such sixty (60) day period. If Senetek
elects, in its sole discretion, not to accept Obagi's offer, or if Obagi does
not make an offer within the aforementioned sixty (60) day period, Senetek shall
be free to (a) grant such rights for such new product to other parties (PROVIDED
that the terms granted to any such other party, taken

                                       5
<PAGE>

as a whole, shall not be more favorable to such other party than (x) terms
offered by Obagi to Senetek, or (y) if Senetek made a counteroffer to Obagi
within the aforementioned sixty (60) day period, the terms contained in such
counteroffer), or (b) exercise such rights itself.

         2.5 Senetek hereby grants Obagi a right of first offer to obtain
exclusive licenses and rights to market, distribute and sell in the Territory
any and all cosmaceutical products to be developed in the future by Senetek and
to be sold in the Market, including, without limitation, cosmaceutical products
to be developed by Senetek in collaboration with the University of Aarhus.
Senetek shall give Obagi written notice that any such new product is or may
become available for distribution and sale. During the sixty (60) day period
following Obagi's receipt of such written notice, Obagi may deliver an offer to
Senetek setting forth an offer to purchase, market, distribute and/or sell such
new product. If Obagi makes any such offer, Senetek and Obagi shall negotiate in
good faith toward reaching a formal agreement through the remainder of such
sixty (60) day period. If Senetek elects, in its sole discretion, not to accept
Obagi's offer, or if Obagi does not make an offer within the aforementioned
sixty (60) day period, Senetek shall be free to (a) grant such rights for such
new product to other parties (PROVIDED that the terms granted to any such other
party, taken as a whole, shall not be more favorable to such other party than
(x) terms offered by Obagi to Senetek, or (y) if Senetek made a counteroffer to
Obagi within the aforementioned sixty (60) day period, terms contained in such
counteroffer), or (b) exercise such rights itself.

         2.6 In the event Obagi and Senetek reach agreement with respect to any
offer make by Obagi pursuant to Sections 2.4 or 2.5, the parties shall amend
this Agreement to incorporate the terms of such additional agreement; PROVIDED,
HOWEVER, the parties agree that the royalty rate as set forth in Section 3.3
shall not be changed as a result of such amendment.

         2.7 It is expressly understood that this Agreement grants no rights to
Obagi for the sale of the Product or under any patents related thereto except
those express rights set forth in Sections 2.1 through 2.6. Without limiting the
foregoing, it is understood and agreed that Obagi shall (i) not sell the
Products outside the Territory or within any Territory outside the Market
specified with respect thereto, (ii) use diligent commercially reasonable
efforts, within the constraints of applicable law, to terminate future sales of
Products to any customer who sells the Products outside the Territory or within
any Territory outside the Market specified with respect thereto after obtaining
actual knowledge by an officer of Obagi of such a sale by a customer or receipt
of written notice from Senetek of such a sale, (iii) not manufacture or have
made other than by Senetek or its designee any Products, PROVIDED that if
Senetek fails to provide Products in such quantities as are ordered by Obagi
within the time provided herein (whether or not such failure is in accordance
with Section 11.9), Obagi may manufacture or have made other than by Senetek or
its designee any Products during the period of, and to the extent of, such
failure by Senetek, and Senetek shall promptly grant Obagi or its designee such
rights (including Intellectual Property) to the extent necessary to manufacture
such Products, and (iv) not have any right with respect to Improvements except
as set forth in Section 2.4. Upon any termination of this Agreement, Obagi shall
have no right of any kind with respect to the Products, Patents or Improvements
other than the right to complete the sale of Products then lawfully in its
possession subject to the payment of royalties pursuant to Section 3.3(a).

                                       6
<PAGE>

                                   ARTICLE III
                            TERMS OF LICENSE AND SALE

         3.1 In consideration of the exclusive licenses and rights set forth in
Article II, Obagi shall pay Senetek One Million One Hundred Fifty Thousand
Dollars ($1,150,000), which shall be payable as follows:

                  (a) Two Hundred Fifty Thousand Dollars ($250,000) on the
Effective Date (which amount shall be reduced by a credit of Obagi's previous
payment to Senetek of One Hundred Thousand Dollars ($100,000));

                  (b) Two Hundred Thousand Dollars ($200,000) on
December 31, 1999;

                  (c) Two Hundred Thousand Dollars ($200,000) on June 30, 2000;

                  (d) Two Hundred Fifty Thousand Dollars ($250,000) on September
30, 2000; and

                  (e) Two Hundred Fifty Thousand Dollars ($250,000) on
December 31, 2000.

         3.2 The purchase price payable by Obagi for Products (including
packaging, labeling and delivery to Obagi, in each case pursuant to Obagi's
specifications) shall be as follows:

                  (a) With respect to Products to be distributed and sold in
Taiwan, [***] percent [***]% of Senetek's Actual Direct Net Cost for such
Products; and

                  (b) With respect to Products to be distributed and sold in all
Territories other than Taiwan, [***] percent [***]% of Senetek's
Actual Direct Net Cost for such Products.

All amounts payable pursuant to this Section 3.2 shall be paid within twenty-one
(21) days after Senetek delivers to Obagi a written invoice therefor. Late
payments shall be subject to a monthly processing fee of one percent (1%) of the
amount overdue or, if such amount is not permitted by law, the maximum amount
permitted by law. Senetek shall send Obagi written invoices for purchased or
ordered Products only concurrently with or after shipment to Obagi of all items
of Product included in such invoice. Senetek shall use commercially reasonable
efforts to prevent Product price increases during the Term. Obagi and Senetek
shall work together on Product cost reduction programs, which may include an
Asian manufacturing site. Any savings resulting from any such cost reduction
program (net of any out-of-pocket expenses incurred by Senetek in connection
with the realization of such savings) shall be shared equally between Senetek
and Obagi; PROVIDED, HOWEVER, except for the reduction of the amount payable as
a result of the portion of the cost savings allocated to Obagi, there shall be
no reduction in the Actual Direct Net Cost for the purpose of determining the
amount payable pursuant to this Section 3.2 (for example, if the cost of
Products sold in Taiwan is reduced from $[***] to $[***] per unit, the amount

                                       7

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

payable by Obagi following such reduction shall be $[***] per unit ([***]% x
$[***] minus [***] of the $[***] cost reduction)).

         3.3 (a) Obagi shall pay royalties to Senetek based on a percentage of
Obagi's total aggregate cumulative Net Sales of Products in the Territories
during such Contract Year, as follows:

<TABLE>
<CAPTION>
                                                   Royalty Payable (Expressed as Percentage of
Total Aggregate Cumulative Net Sales of            Obagi's Total Aggregate Cumulative
Products During Contract Year                      Net Sales of Products in the Territories)
-----------------------------------------          --------------------------------------------
<S>                                               <C>
         Less than $[***]                                               [***]%
         $[***] to $[***]                                               [***]%
         $[***] to $[***]                                               [***]%
         $[***] to $[***]                                               [***]%
         $[***] to $[***]                                               [***]%
         $[***] or more                                                 [***]%
</TABLE>

Obagi shall pay Senetek, within thirty (30) days of the end of each quarterly
period (ending June 30, September 30, December 31, and March 31) of each
Contract Year, any incremental royalties accrued during such quarterly period
then ended. Late payments shall be subject to a monthly processing fee of one
percent (1%) of the amount overdue or, if such amount is not permitted by law,
the maximum amount permitted by law. Obagi shall deliver with the payment a
statement setting forth the Net Sales of Products in each of the Territories and
the manner in which such royalty payment was calculated.

                  (b) As an incentive to market the Products in the Territories,
Senetek shall credit Obagi's obligations to pay royalties pursuant to subsection
3.3(a) in the aggregate amount of $[***] per Contract Year for each of the
second, third and fourth Contract Years, which shall be spread in equal credits
of $[***] applicable to each quarterly royalty payment payable during the
second, third and fourth Contract Year. Such credit shall only be applicable on
any royalty payment date so long as, on such royalty payment date, (i) Obagi has
not breached any material provision of this Agreement in any material respect,
(ii) Obagi shall have met or exceeded the minimum order requirements for all
prior periods, and (iii) except to the extent delayed by applicable laws or
regulatory authorities, Obagi shall have launched in Taiwan, Singapore, Hong
Kong and Japan not later than the Target Launch Date therefor.

         3.4 Each party shall keep books and records sufficient to verify the
accuracy and completeness of its accounting referred to above, including without
limitation inventory, cost, sales, purchase and invoice records relating to the
Products or their manufacture, purchase and sale. Such books and records shall
be preserved for a period not less than six (6) years after they are created
during and after the Term of this Agreement.

         3.5 Each party shall take commercially reasonable steps necessary so
that the other party may, within thirty (30) days of its request and review all
the books and records at a single

                                       8

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

United States location to verify the accuracy of the other party's accounting.
Such review may be performed by any employee of the requesting party as well as
by any attorney or licensed certified public accountant designated by the
requesting party, upon reasonable notice and during regular business hours. Each
party shall conduct no more than one (1) review during any Contract Year.

         3.6 All Products shall be delivered to Obagi: F.O.B. the manufacturer.

                                   ARTICLE IV
                          FORECASTS, SHIPMENTS, ORDERS

         4.1 Each thirty (30) days, Obagi shall provide Senetek with an updated
forecast of Obagi's Product purchases during the next following ninety (90) day
period (but not extending beyond the Term). Obagi shall provide its initial
forecast within two (2) weeks after registration of any of the Products for sale
in Taiwan. Such forecasts of Obagi's Product purchases shall be deemed an order
for such Products which is non-cancellable (unless Senetek shall have breached
this Agreement). Additional Product may be ordered by Obagi in such quantities
as Obagi may from time notify Senetek pursuant to Obagi's standard form purchase
orders, a copy of which form is attached as EXHIBIT B (it being understood, for
the avoidance of doubt, that in the event of, and only to the extent of, a
conflict between the provisions of this Agreement and Obagi's standard form
purchase orders, the terms of this Agreement shall control). Senetek shall
deliver to Obagi all Products ordered in a forecast within thirty (30) days
after the date specified for delivery of such Products in such forecast;
PROVIDED, HOWEVER, that in the event that any order for additional Product Units
is placed by purchase order or by an increase in any ninety (90) day forecast of
the amount of Product Units ordered during any month covered by any prior
forecast, Senetek shall use commercially reasonable efforts to deliver such
additional Product on or prior to the delivery date requested in such Purchase
Order or in such revised forecast but shall have no liability to Obagi (and
Obagi agrees to accept delivery of such order) so long as such additional Units
are shipped within ninety (90) days of the date of delivery of such revised
forecast or Purchase Order. The parties understand that the lead time for
delivery of the initial order will be dependent on Obagi's packaging
requirements.

         4.2 Obagi shall order the following minimum amounts of Product from
Senetek for distribution and sale in the Territories (each a "MINIMUM
PURCHASE REQUIREMENT"): (a) for the period from April 1, 2000 through March
31, 2001, a non-cancelable order for 1,000,000 Units; (b) for the period from
April 1, 2001 through March 31, 2002, a non-cancelable order for 1,200,000
Units; and (c) for each subsequent period from April 1 of a calendar year
through March 31 of the next following calendar year through the remainder of
the Term, such minimum amounts as shall be agreed to by Senetek and Obagi by
September 30, 2001, but not less than a ten percent (10%) increase in the
actual base business for a particular market from the prior six-month trend,
PROVIDED that in the event that a market is declining for such reasons as are
beyond the reasonable control of Obagi to which Senetek and Obagi may agree
to, the minimum increases may be reduced or eliminated; PROVIDED, FURTHER,
that the parties shall negotiate in good faith a reduction or elimination of
Minimum Purchase Requirements in effect following a Patent Termination Date.
If Obagi shall fail to meet its Minimum Purchase Requirement for any period

                                       9

<PAGE>

after March 31, 2002, Senetek's sole remedies shall be either (i) termination of
this Agreement pursuant to Article X or (ii) the termination of the exclusivity
of the license granted hereby pursuant to Section 2.2 hereof.

         4.3 Obagi grants to Senetek a license to utilize the trademarks,
service marks and other Intellectual Property necessary to package and label
the Products to be sold to Obagi (the "PACKAGING LICENSE"). The Packaging
License shall expire upon the termination of this Agreement.

                                    ARTICLE V
                         MARKETING; REGULATORY APPROVALS

         5.1 Obagi shall allocate a consolidated marketing and promotion
budget (which shall include an allocation of Obagi's marketing department to
the extent related to direct consumer marketing in the Territories) to
promote the sale of Products in an amount not less than (a) in the case of
all Territories other than Japan, [***] percent ([***]%) of Obagi's Net Sales
of Products in such Territories during the Contract Year of the Term, and (b)
in the case of Japan, (i) [***] percent ([***]%) of Obagi's Net Sales of
Products in Japan during the first Contract Year after launch in Japan and
(ii) for the subsequent Contract Years, such amounts as the parties shall
annually agree to establish, but in no event less than [***] percent ([***]%)
of Obagi's Net Sales of Products in Japan during any such Contract Year.

         5.2 Except as provided below in this Section 5.2, Obagi shall be
solely responsible for and shall take commercially reasonable actions to
register the Products for sale in, and obtain all other governmental
approvals necessary to sell the Products from the government of, each
Territory. Senetek shall provide commercially reasonable assistance to Obagi
in connection with, and shall promptly provide Obagi with all necessary
information within its possession, and shall use commercially reasonable
efforts to obtain and provide Obagi with all other necessary information, for
the full and legal registration of Products in each Territory.

         5.3 The parties agree that Obagi may assign its rights, but not its
obligations, under this Agreement with respect to Japan to a joint venture
that may be created by Obagi and Rohto Pharmaceutical Co., provided that such
joint venture consents to be bound by this Agreement. Upon the creation of
such joint venture, Obagi and Senetek agree to jointly announce such joint
venture and the involvement of Products in such arrangement.

         5.4 Senetek shall submit to Obagi for review and approval (which
approval shall not be unreasonably delayed or withheld), prior to release, of
all press releases containing any information relating to Obagi, Obagi's Asian
partners, or the Products. Obagi shall submit to Senetek for review and approval
(which approval shall not be unreasonably delayed or withheld), prior to
release, of all press releases containing any information relating to Senetek or
the Products. Notwithstanding the foregoing, each party agrees that the other
party may make such public statements as are required by applicable securities
laws or the rules of any exchange on which securities of such party or its
Affiliates are listed.

                                       10

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                                   ARTICLE VI
                    REPRESENTATIONS, WARRANTIES AND COVENANTS

         6.1 Each of the parties hereto represents and warrants to the other
that: (i) it is duly organized, validly existing and in good standing in
accordance with the laws of its jurisdiction of organization; (ii) it has all
requisite legal and corporate power and authority to enter into and perform its
obligations under this Agreement; (iii) it has duly authorized the entry into
and performance of its obligations under this Agreement by all requisite
corporate actions; (iv) when executed by the corporate officers whose names
appear on the signature page hereof, this Agreement shall be a legal, valid and
binding obligation of such party enforceable in accordance with its terms,
subject to bankruptcy, insolvency and similar laws affecting creditors' rights
generally and general principles of equity; (iv) its execution and delivery and
performance of its obligations under this Agreement do not breach, violate,
conflict with or contravene in any material respect (A) its organizational
documents, (B) any laws, rules, regulations, orders, judgments or decrees
applicable to or binding upon such party or its property, or (C) any other
agreement, instrument, mortgage, indenture, contract, license or other document
to which it is a party or by which it is bound; (v) it has obtained all
governmental and third party consents and made all filings and notices required
in connection with its execution, delivery and performance of this Agreement,
and all such consents, filings and notices remain in full force and effect; and
(vi) it will comply in all material respects with all applicable laws, rules and
regulations in the conduct of its responsibilities and activities under this
Agreement.

         6.2 Senetek represents, warrants and covenants to Obagi that: (a) all
Products will conform in all material respects to the specifications to be
agreed to by the parties prior to the date on which Obagi provides its initial
order for Product or from time to time hereafter; (b) Senetek and the
manufacturer(s) of all Products have and will comply in all material respects
with good manufacturing practices and all laws, regulations, rules and orders
covering the production, sale and delivery of Products from which, because of
noncompliance by Senetek or such manufacturer(s), liability (other than de
minimis monetary liability) may accrue to Obagi; (c) all Products have been and
will be produced in compliance with applicable requirements of the Fair Labor
Standards Act of 1938, as amended, Executive Order 11246, and all rules,
regulations and orders of the Secretary of Labor of the United States of
America, in each case to the extent applicable and to the extent Obagi could
have liability as a result of such noncompliance; (d) Senetek has, and
throughout the Term at all times shall maintain at Senetek's sole expense,
sufficient right, title and interest in all Intellectual Property (other than
the Packaging License and other Intellectual Property owned by Obagi) necessary
to produce and license Product A for sale in the Primary Territories; (e)
Senetek holds each item of registered or registrable Intellectual Property
(including, without limitation, patents, trademarks, trade names, and
applications for any of the foregoing (including the status of such applications
and any rejections or challenges thereof)) listed on EXHIBIT A attached; (f)
there are no interference, opposition or cancellation proceedings pending or, to
the knowledge of Senetek, threatened against any of the Intellectual Property
listed on EXHIBIT A; (g) no claim, suit or action to which Senetek is a party or
which is known to Senetek is pending or, to Senetek's knowledge, threatened
alleging that any Product is infringing or would infringe upon the Intellectual
Property rights of others; (h) Product A and the license or right granted or
purported to be granted to

                                       11
<PAGE>

Obagi pursuant to this Agreement with respect thereto will not infringe,
violate or otherwise impair any Intellectual Property rights in the United
States or any of the Primary Territories (it being understood that Senetek
(1) does not represent, warrant or covenant that Senetek's rights granted to
Obagi hereunder are exclusive, but (2) does represent, warrant and covenant
that Senetek has not granted, and will not grant, any of such rights to any
other person or entity other than Obagi); (i) Senetek shall use all
commercially reasonable efforts to obtain (as soon as possible after the
Effective Date) and thereafter maintain at all times, in each case at
Senetek's sole expense, sufficient right, title and interest in all patents
necessary to produce and license Product A for sale in Hong Kong and
Singapore; (j) upon obtaining any patent referred to in CLAUSE (i) above with
respect to Hong Kong or Singapore, Senetek shall immediately notify Obagi
thereof in writing; (k) upon (x) obtaining the patents referred to in CLAUSE
(i) above with respect to Hong Kong or Singapore and (y) the expiration of
any applicable period for government agency or judicial review for
challenging the issuance of any such patent, and at all times thereafter,
Product A and the license or right granted or purported to be granted to
Obagi pursuant to this Agreement with respect thereto will not infringe,
violate or otherwise impair any patent in such Territory (it being understood
that Senetek (1) does not represent, warrant or covenant that Senetek's
rights granted to Obagi hereunder are exclusive, but (2) does represent,
warrant and covenant that Senetek has not granted, and will not grant, any of
such rights to any other person or entity other than Obagi); and (l) as of
the Effective Date, the Actual Direct Net Cost for units of products which
are comparable to Units of the Products and which are being sold by Senetek
to its customers is approximately $[***] for units of 2 ounces or less and
approximately $[***] for units of 4 ounces or more.

         6.3 Obagi represents, warrants and covenants to Senetek that the
Packaging License includes all the Intellectual Property rights necessary for
Senetek to produce the packaging and labeling required by this Agreement.

         6.4 Notwithstanding any representation or warranty made by Senetek in
Section 6.2, (a) Obagi understands and agrees that, as of the Effective Date,
Senetek has no patents or patent applications pending with regard to (i) the
Products in any Secondary Territory or (ii) Product B in any Territory, and (b)
Senetek makes no representation or warranty with regard to its Intellectual
Property rights in the Secondary Territory or with regard to Product B,
including without limitation, any representation and warranty that the sale or
the use of Product B in any Territory or any of the Products in the Secondary
Territory does not infringe upon the rights of any other person or entity.

                                   ARTICLE VII
                                 INDEMNIFICATION

         7.1 Obagi shall defend, indemnify, and hold harmless Senetek, its
officers, agents, employees, independent contractors, and Affiliates from any
claim or action arising out of or related to a breach of any representation,
warranty or covenant made by Obagi herein, or the handling, possession,
marketing or sale of the Products, in each case, by Obagi or its customers
(including the use of the Packaging License), except insofar as such claims are
related to or arise from Senetek's negligence or breach of this Agreement and
except for Intellectual Property

                                       12

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

infringement, violation or other impairment (other than in respect of the
Packaging License) and product liability claims (except to the extent such
product liability claims relate to the packaging of the Products or the
mishandling of the Products by Obagi or its customers).

         7.2 Senetek shall defend, indemnify, and hold harmless Obagi, its
officers, agents, employees, independent contractors, and Affiliates from any
claim or action arising out of or related to a breach or alleged breach of any
representation, warranty or covenant made by Senetek herein, or the handling or
sale of the Products by Senetek or the manufacturer thereof, or the manufacture
or use of the Products, or is based upon a claim that any Product, as such,
infringes, violates or otherwise impairs any Intellectual Property rights or any
other proprietary right of any third party, except insofar as (i) such claims
are related to or arise from Obagi's negligence or breach of this Agreement or
(ii) such claims relate to any matter to which Senetek expressly disclaimed any
representation and warranty in Section 6.4 of this Agreement.

         7.3 In the event of any such claim or action by any third party, the
party seeking indemnification hereunder (the "INDEMNIFIED PARTY") agrees: (i) to
give the party required to indemnify the Indemnified Party (the "INDEMNIFYING
PARTY") reasonably prompt notice of the claim or action; and (ii) to provide the
Indemnifying Party with information, assistance and authority necessary, at the
Indemnifying Party expense, to enable the Indemnifying Party to defend such
claim or action. After receipt of any such notice, the Indemnifying Party shall
have the right to (x) take control of the defense and investigation of such
lawsuit or action, (y) employ and engage attorneys of its own choice (which
shall be reasonably acceptable to the Indemnified Party) to handle and defend
the same, at the Indemnifying Party's sole cost and expense, and (z) compromise
or settle such claim, which compromise or settlement shall be made only after
consultation and with the written consent of the Indemnified Party (such consent
not to be unreasonably withheld, delayed or denied); PROVIDED, HOWEVER, no such
consent will be required if such settlement provides solely for payment of
monetary damages for which the Indemnified Party will be indemnified in full.
The Indemnified Party may participate in the investigation, trial and defense of
any such third party action and any appeal arising therefrom at its sole cost
and expense.

         7.4 If any claim involving infringement, violation or impairment of any
kind of Intellectual Property for which Senetek is obligated to indemnify Obagi
pursuant to Section 7.2 of this Agreement is resolved in a manner that precludes
Senetek from granting any right included in the Intellectual Property, Senetek
will, at Senetek's expense:

                  (a) procure such license as is necessary for Obagi's past
rights and future rights to continue to exercise all rights granted with respect
to the Product(s) under this Agreement;

                  (b) replace or modify the allegedly infringing item(s) to
avoid the infringement, without materially impairing performance or compliance
with the Product's specifications to Obagi's reasonable satisfaction, or

                                       13
<PAGE>

                  (c) if neither the procuring of such a license nor the
replacement or modification as above-described are economically practicable,
accept return of all the Product(s) purchased.

         7.5 Each party's obligations under this Article VII shall survive the
expiration of the Term indefinitely.

         7.6 Each Indemnified party shall be entitled to offset against
royalties or any other obligations owed by such party to the Indemnifying Party
the sum of all Indemnifable Damages that such Indemnified party is entitled to
pursuant to Article VII hereof; PROVIDED, HOWEVER, no Indemnified Party shall
offset any amounts due by such party to the other party hereto unless and until
such claim for Indemnifable Damages has been finally judicially determined to be
a valid claim for indemnification under this Article VII (which judicial
determination shall no longer be subject to appeal) or the parties mutually
agree that such claim is a valid claim for indemnification.

         7.7 Each party shall maintain at its expense commercial general
liability insurance in a principal amount of not less than the coverage
generally maintained by companies of similar size in its industry. Each party
shall also maintain a product liability policy relating to any use of the
Products at any time after the date of this Agreement with coverage of not
less than One Million Dollars ($1,000,000) per occurrence and Ten Million
Dollars ($10,000,000) in the aggregate. Each of the policies required under
this Section 7.7 and maintained by any party shall name the other party as an
additional insured and require the insurer to provide at least thirty (30)
days written notice to such other party before any cancellation or material
change to the limits, deductibles or terms of such policies. Within thirty
(30) days after the date of this Agreement, each party shall furnish to the
other party certificates evidencing its insurance, such other party's
designation as additional insured, and such notice requirement. Any party may
elect to suspend its performance under this Agreement until any insurance
required to be maintained by the other party is in place and such
certificates of coverage are provided, and may thereafter suspend its
performance if it reasonably believes such insurance is not in place until
the party required to maintain such coverage provides the other party
reasonable assurance that such coverage is in place without any gap in
coverage during the Term and will be maintained as required by this Agreement.

                                  ARTICLE VIII
                            CONFIDENTIAL INFORMATION

         8.1 Obagi shall not (a) use Senetek Confidential Information except to
perform its obligations under this Agreement, or (b) disclose Senetek
Confidential Information to any person or entity (except to its employees and
agents who reasonably require same for the purpose hereof and who are bound to
Obagi by the same obligations as to confidentiality) without the express written
permission of Senetek, unless such disclosure is required by a governmental
authority or by order of a court of competent jurisdiction.

                                       14

<PAGE>

         8.2 Senetek shall not (a) use Obagi Confidential Information except to
perform its obligations under this Agreement, or (b) disclose Obagi Confidential
Information to any person or entity (except to its employees and agents who
reasonably require same for the purpose hereof and who are bound to Senetek by
the same obligations as to confidentiality) without the express written
permission of Obagi, unless such disclosure is required by a governmental
authority or by order of a court of competent jurisdiction.

         8.3 The furnishing of confidential information by one party to the
other shall not constitute any grant, option or license to the other under any
patent or other rights now or hereafter held by the furnishing party.

         8.4 The provisions of this Article VIII shall survive termination of
this Agreement and continue for a period of ten (10) years.

                                   ARTICLE IX
                                     RECALLS

         9.1 In the event any Product(s) must be recalled from the channel of
distribution by reason of failure to meet any requirements of law or otherwise,
Obagi shall have the sole responsibility to effect the recall. Senetek shall use
its reasonable best efforts to cooperate with Obagi in implementing any such
recalls to the extent such cooperation is necessary to effect the recall.

         9.2 In the event the recall results from or is caused by an act or
omission by Obagi, Obagi shall reimburse Senetek for any costs and/or expenses
reasonably expended by Senetek as a consequence of the recall. Without limiting
the general nature of the foregoing, Obagi shall bear the cost of (a) any
Product involved in such recall, (b) any other raw materials used to produce
recalled Products, and (c) the purchase price payable pursuant to Section 3.2
for any Products that are recalled and for any other finished Products that
cannot be shipped due to the condition requiring the recall.

         9.3 In the event the recall results from or is caused by an act or
omission of Senetek, Senetek shall reimburse Obagi for any costs and/or expenses
reasonably expended by Obagi as a consequence of the recall. Without limiting
the general nature of the foregoing, Senetek will provide replacement Products
for recalled Products and for any Products that cannot be shipped due to the
condition requiring the recall.

                                    ARTICLE X
                                   TERMINATION

         10.1 Except as otherwise provided herein, each party shall have the
right, but not the obligation to terminate this Agreement at any time upon
written notice to the other in the event the other party fails to perform any
material obligation and such failure continues for a period of thirty (30) days
after notice thereof with respect to a payment failure or, with respect to any
other failure, such failure continues for a period of sixty (60) days after
notice thereof. This

                                       15
<PAGE>

Agreement shall terminate automatically, and without the necessity of notice or
any other action, if any party is declared insolvent or bankrupt by a court of
competent jurisdiction, or a voluntary petition of bankruptcy is filed in any
court of competent jurisdiction by any party, or any party makes or executes any
assignment for the benefit of creditors.

         10.2 Senetek shall have the right, but not the obligation, to terminate
(a) the exclusivity of the licenses and rights granted to Obagi in this
Agreement by written notice to Obagi within 180 days of the end of any Contract
Year in the event that Obagi failed to satisfy the Minimum Purchase Requirement
as set forth in Section 4.2, or (b) the licenses and rights granted to Obagi
pursuant to this Agreement as to Japan, by giving written notice to Obagi on or
prior to March 31, 2000, in the event that Obagi has failed to (i) enter into a
joint venture arrangement with Rohto Pharmaceutical Co. or another company
reasonably acceptable to Senetek, and/or (ii) assign its rights to sell the
Products in Japan under this Agreement to Rhoto Pharmaceutical Co., such joint
venture, or such other company reasonably acceptable to Senetek, in each case,
on or prior to February 29, 2000.

                                   ARTICLE XI
                                  MISCELLANEOUS

         11.1 The validity, interpretation and performance of this Agreement
shall be governed and construed in accordance with the internal laws (without
application of conflict of laws principles thereof) of the State of California.

         11.2 Except as otherwise provided herein, neither party may assign this
Agreement is without the prior written consent of the other party hereto,
PROVIDED that this Agreement may be assigned (a) to the surviving entity in the
event of a merger of a party with and into another party and (b) to the
purchaser of all or substantially all of the assets of any party. This agreement
shall be binding upon, and inure to the benefit of, Obagi and Senetek and their
respective successors and permitted assigns.

         11.3 This Agreement constitutes the full understanding of the parties
and is a complete and exclusive statement of the terms of their agreement. All
prior agreements, negotiations, dealings and understandings, whether written or
oral, regarding the subject matter hereof, are hereby superseded and merged into
this Agreement.

         11.4 This Agreement shall not be modified, rescinded or waived except
in writing signed by the party to be bound thereby.

         11.5 Any notice, request, approval or other document required or
permitted to be given under this Agreement shall be in writing and shall be
deemed to have been sufficiently given when delivered in person or by courier
service of established reputation to the President of the subject party at the
address for such subject party specified in the Preamble hereto or to such other
address as may be specified from time to time in a written notice to the other
party.

                                       16
<PAGE>

         11.6 Section and article headings are provided for convenience of the
parties only and shall not be construed as a part of this Agreement or a
limitation on the scope of the particular sections and articles to which they
refer.

         11.7 If any term or provision of this Agreement or any application
thereof shall be invalid or unenforceable, the remainder of this Agreement or
any other application of such term or provision shall not be affected hereby.

         11.8 This Agreement may be executed in two or more counterparts, each
of which shall constitute an original and all of which together shall constitute
a single instrument.

         11.9 The performance or observance by either party of any obligations
of such party under this Agreement may be suspended by it, in whole or in part
and without liability, in the event of any of the following which prevents such
performance or observance: (a) Act of God, war, riot, uprising, fire, explosion,
accident, flood, sabotage, strike, lockout or injunction; (b) inability to
obtain fuel, power, raw materials, labor, containers or transportation
facilities; (c) breakage or failure of machinery or apparatus; (d) national
defense requirements; (e) compliance with governmental laws, regulations, rules,
orders or actions; or (f) any other cause (whether similar or dissimilar) beyond
the reasonable control of such party; PROVIDED, HOWEVER, that the party so
prevented from complying with its obligations shall immediately notify in
writing the other party thereof and such party so prevented shall exercise
diligence in an endeavor to remove or overcome the cause of such inability to
comply, and PROVIDED FURTHER that neither party shall be required to settle a
labor dispute against its own best judgment.

         11.10 ALL ACTIONS OR PROCEEDINGS IN ANY WAY, MANNER OR RESPECT, ARISING
OUT OF OR FROM OR RELATED TO THIS AGREEMENT SHALL BE LITIGATED IN COURTS HAVING
SITUS WITHIN THE STATE OF CALIFORNIA. THE PARTIES HEREBY CONSENT AND SUBMIT TO
THE JURISDICTION OF ANY LOCAL, STATE OR FEDERAL COURTS LOCATED WITHIN SAID
STATE, AND EACH PARTY HEREBY IRREVOCABLY WAIVES ANY OBJECTION IT MAY HAVE BASED
UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE OR FORUM NON CONVENIENS.

         11.11 It is not the intent of the parties hereto to form any
partnership or joint venture. Each party shall, in relation to its obligations
hereunder, act as an independent contractor, and nothing in this Agreement shall
be construed to give either party the power or authority to act for, bind or
commit the other.

         11.12 EXCEPT FOR CLAIMS THAT INCLUDE CONSEQUENTIAL DAMAGES PAID TO
PERSONS THAT ARE NOT AN INDEMNIFIED PARTY OR AFFILIATES THEREOF, NEITHER PARTY
SHALL BE LIABLE TO THE OTHER FOR CONSEQUENTIAL, PUNITIVE, EXEMPLARY, INCIDENTAL
OR SPECIAL DAMAGES, LOST PROFITS (OTHER THAN LOST PROFITS TO THE EXTENT
ATTRIBUTABLE SOLELY TO ANY BREACH BY OBAGI OF SECTIONS 4.2(A) OR (B) HEREOF),
INJURY TO REPUTATION OR SIMILAR CLAIMS. UNDER NO

                                       17
<PAGE>

CIRCUMSTANCES SHALL SENETEK OR ITS AFFILIATES HAVE ANY LIABILITY ARISING FROM
THIS AGREEMENT IN EXCESS OF THE HIGHEST AGGREGATE AMOUNT PAID AS PURCHASE PRICE
AND ROYALTIES OVER THE COURSE OF ANY PERIOD OF TWO CONSECUTIVE CONTRACT YEARS.
UNDER NO CIRCUMSTANCES SHALL OBAGI OR ITS AFFILIATES HAVE ANY LIABILITY ARISING
FROM THIS AGREEMENT IN EXCESS OF THE HIGHEST AGGREGATE AMOUNT PAID AS PURCHASE
PRICE AND ROYALTIES OVER THE COURSE OF ANY PERIOD OF TWO CONSECUTIVE CONTRACT
YEARS.

                                       18
<PAGE>

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.

                                  SENETEK PLC

                                  By     [ILLEGIBLE]
                                    ---------------------------------------
                                  Name:   [ILLEGIBLE]
                                       ------------------------------------
                                  Title: Chariman & CEO
                                        -----------------------------------

                                  OBAGI MEDICAL PRODUCTS, INC.

                                  By      [ILLEGIBLE]
                                    ---------------------------------------
                                  Name:     [ILLEGIBLE]
                                       ------------------------------------
                                  Title: President & CEO
                                        -----------------------------------

                [Signature Page to License and Supply Agreement]

<PAGE>

                                   EXHIBIT A
                                 -------------

                                PATENTS GRANTED
                           (USE-PATENT FOR PRODUCT A)
<TABLE>
<S>                                                    <C>
         -------------------------------------------------------------
               COUNTRY                                  PATENT NO.
         -------------------------------------------------------------
               CHINA                                    ZL91104472.8
         -------------------------------------------------------------
               TAIWAN                                      076376
         -------------------------------------------------------------
            SOUTH KOREA                                  196660
         -------------------------------------------------------------
</TABLE>

                          PATENT APPLICATIONS PENDING
                           (USE-PATENT FOR PRODUCT A)

                                     JANPAN
                                    MALAYSIA
                                  PHILIPPINES<PAGE>

              ALLODERM-Registered Trademark- CO-PROMOTION AGREEMENT

         THIS ALLODERM CO-PROMOTION AGREEMENT (the "Agreement") is made and
entered into this 9th day of February, 2000 (the "Effective Date"), by and
between Obagi Medical Products, Inc. ("OMP"), a California corporation, and
LifeCell Corporation. ("LifeCell"), a Delaware corporation. OMP and LifeCell are
collectively referred to as the "Parties."

                                    RECITALS

         WHEREAS, LifeCell is a bioengineering company engaged in the
development and commercialization of tissue regeneration and cell preservation
products and holds all right, title and interest in and to AlloDerm acellular
dermal graft ("AlloDerm-Registered Trademark-");

         WHEREAS, AlloDerm is prepared in two forms: prepackaged for injection
in several sizes of syringes ("Micronized AlloDerm-TM-"), and prepackaged in
several sizes in sheet form, and this Agreement relates only to Micronized
AlloDerm-TM-;

         WHEREAS, OMP desires to secure exclusive rights from LifeCell for a
specific term for the co-promotion of the Products in specified markets in
identified geographic regions pursuant to the terms and conditions herein
provided; and

         WHEREAS, LifeCell desires to provide exclusive rights to OMP for a
specific term for the co-promotion of the Products (as defined in Section 1) in
specified markets in identified geographic regions pursuant to the terms and
conditions herein provided;

         NOW, THEREFORE, in consideration of the mutual covenants and promises
recited below, the parties, intending to be legally bound, agree as follows:

                              TERMS AND CONDITIONS

I.       DEFINITIONS

         As used in this Agreement, the following capitalized terms shall have
the following respective meanings:

         "AFFILIATE" shall mean (a) any company owned or controlled to the
extent of at least fifty percent (50%) of its issued and voting capital
securities by a party to this Agreement and any other company so owned or
controlled (directly or indirectly) by any such company or the owner of any such
company, or (b) any partnership, joint venture or other entity directly or
indirectly controlled by, controlling, or under common control of, to the extent
of fifty percent (50%) or more of voting power (or otherwise having power to
control its general activities) by a party to this Agreement, but in each case
only for so long as such ownership or control shall continue.

         "cc" shall mean the unit of volume equal to one (1) cubic centimeter.

<PAGE>

         "COMPETITIVE PRODUCTS" shall mean injectable augmentation products
used in reconstructive plastic surgery by office-based dermatologists and
office-based plastic surgeons.

         "CONTRACT YEAR" shall mean each consecutive twelve month period, with
the first Contract Year beginning on January 1, 2000.

         "COST OF GOODS SOLD" shall mean LifeCell's manufacturing cost for each
Unit of Product including direct labor, direct material and manufacturing
overhead allocated on a basis consistent with all of LifeCell's finished goods,
but excluding any extraordinary or non-recurring charges, and expenses or costs
related to the start-up of manufacturing of Micronized AlloDerm-TM- in
commercial quantities.

         "COST OF GOODS SOLD PERCENTAGE" shall mean the average, for any six (6)
consecutive months, of the Cost of Goods Sold per Unit divided by the Net Sales
Per Unit.

         "DATE OF COMMERCIALIZATION" shall mean the calendar date three business
days after LifeCell first ships any Product to OMP.

         "DISTRIBUTION AMOUNT" shall mean [***]% of Net Sales, retained by OMP
to offset costs of distribution.

         "DOLLAR", "DOLLARS" or "$" shall mean the legal currency of the United
States of America.

         "HOLD BACK AMOUNT" shall mean, for the initial Contract Year, the
percentage of the LifeCell Amount equal to OMP's reserve for bad debts, as
determined in accordance with United States generally accepted accounting
principles, expressed as a percentage of OMP's accounts receivable with respect
to the end of the immediately preceding fiscal year. The Initial Hold Back
Amount shall be [***] percent ([***]%). The Hold Back Amount for all subsequent
Contract Years shall mean the percentage of the LifeCell Amount equal to OMP's
Actual Bad Debt (as defined below) directly related to the sale of Product for
the immediately preceding Contract Year expressed as a percentage of OMP's
accounts receivable with respect to the sale of Product. "Actual Bad Debt"
shall mean OMP's customer accounts for the sale of Product for which payments
are one hundred and twenty (120) days or more past due, and actually written off
against OMP's bad debt reserve account.

         "IMPROVEMENT" means any information, discovery, creation, derivative
work, invention, or trade secret, whether or not patented or patentable or
copyrighted or copyrightable, respecting the Product or derived from human
cadaveric dermis, that is developed or otherwise acquired by either party, their
Affiliates or any of their respective employees, officers or agents.

          "INDEMNIFIABLE DAMAGES" shall mean the sum of all losses, claims,
damages, liabilities, costs, expenses or deficiencies described in Article X.

                                      -2-

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

         "INTELLECTUAL PROPERTY" shall mean (i) patents and patent
applications, (ii) trademarks, trade names, service marks and registrations
and applications for registrations thereof (including, but not limited to,
"AlloDerm-Registered Trademark-," "Cymetra-TM-" and analogs thereof), (iii)
copyrights and copyright registrations, (iv) trade secrets and secret
processes, and (v) other Know-How, in each case relating to the Product and
in the United States of America and the Territory.

         "JOINT MANAGEMENT COMMITTEE" shall mean the committee formed pursuant
to Article V of this Agreement.

         "KNOW-HOW" shall mean such know-how, special knowledge, data, studies,
technical or other information, whether or not patented or patentable, owned or
controlled by LifeCell at any time prior to or during the Term specifically
related to the Product.

         "LIFECELL AMOUNT" shall mean the amount of all Payable Sales made by
OMP on behalf of LifeCell in any month reduced by the amounts, if any, retained
by OMP for co-promotion fees due to OMP, as calculated in accordance with
Sections 3.3 and 3.4.

         "NET SALES" shall mean the gross revenue recognized from sales of
Product less the amount for returns and allowances as determined in accordance
with generally accepted accounting principles.

         "PAYABLE SALES" shall mean the amount of Net Sales, reduced by the
Distribution Amount.

         "PRODUCT" shall mean Micronized AlloDerm-TM- and any Improvement.
Upon the granting of any licenses and rights as contemplated by Section 2.4
and executing and delivering any amendment of this Agreement as contemplated
by Section 2.4, such additional products for which such license is granted
shall thereafter also be deemed Product.

         "SPECIFICATIONS" shall mean the Product specifications set forth in
Exhibit B annexed hereto and incorporated herein.

         "TERRITORY" shall mean only office-based dermatologists and
office-based plastic surgeons throughout the entire world, as may be modified
by mutual agreement of the Parties pursuant to Section 2.3, PROVIDED,
HOWEVER, that LifeCell's customers, as set forth in Exhibit D annexed hereto
and incorporated herein, are specifically excluded from the Territory.
Notwithstanding any other provision of this Agreement, LifeCell shall retain
the exclusive right to distribute Product in Korea and Brazil, with no rights
to transship from these countries, provided that all Product sold into Korea
and Brazil shall be included in the Minimum Annual Sales of Units sold by OMP
pursuant to section 4.1.

         "UNIT" shall mean an individual unit of Product packaged in
accordance with specifications provided by OMP from time to time and
reasonably acceptable to LifeCell. One Unit of Micronized AlloDerm-TM- shall
be equal to 330 milligrams of Micronized AlloDerm-TM- measured on a dry
weight basis which is to be reconstituted with one cc of diluent.

                                      -3-

<PAGE>

II.      GRANT OF RIGHTS

         2.1 GRANT OF RIGHTS; TERRITORY. In consideration for the execution
and delivery of this Agreement and the ongoing performance by OMP of its
responsibilities and obligations hereunder, and upon the terms and conditions
set forth herein, LifeCell hereby grants to OMP the exclusive right to
promote, market, distribute and sell Micronized AlloDerm-TM- and any
Improvement thereto in the Territory, consistent with the terms and
conditions set forth herein, throughout the Term (as defined in Section
13.1). Except as expressly set forth herein, the license granted hereby
expressly excludes all other rights, including without limitation, the right
to manufacture any Product.

         2.2 INTENTIONALLY DELETED

         2.3 ADDITIONAL TERRITORY. In the event the Parties reach agreement
with respect to the terms and conditions of granting OMP the rights to
promote, market, distribute, and sell the Product in any additional market
segment, pursuant to this Section 2.3, the Parties shall amend this Agreement
to incorporate the terms of such additional terms and conditions into this
Agreement; PROVIDED, HOWEVER, the Parties agree that the revenue allocations
as set forth in Article III shall not be changed as a result of such
amendment.

         2.4 ADDITIONAL PRODUCTS. LifeCell agrees that it will not enter into
any exclusive agreement with any third party for any rights to promote, market,
distribute and sell any and all new products substantially similar to the
Product (including, without limitation, any new injectable tissue augmentation
products and any new products which are substantially similar to the Product
but offered in a different delivery platform), without first providing ten (10)
days written notice to OMP. OMP may, within five (5) business days of receiving
such notice, provide written notice to LifeCell indicating OMP's interest in
obtaining such exclusive rights. Thereafter, the Parties shall meet and use
reasonable commercial efforts to reach a mutually acceptable agreement. Nothing
contained in this Agreement obligates LifeCell or OMP to enter into such an
agreement and either party may terminate negotiations concerning such an
agreement at its sole and exclusive option.

III.     SALES; REVENUE ALLOCATION

         3.1 ONE-TIME PAYMENTS. In consideration of the exclusive licenses and
rights set forth in this Agreement, OMP shall pay LifeCell One Million Dollars
($1,000,000), payable as follows:

         (a) Four Hundred Thousand Dollars ($400,000) in immediately available
             funds on the Effective Date.

         (b) Six Hundred Thousand Dollars ($600,000) in immediately available
             funds on the later of either (i) June 30, 2000 or (ii) the date
             ninety (90) days following the Date of Commercialization;

                                      -4-

<PAGE>

         3.2 SALES REPRESENTATIVE. OMP shall act as LifeCell's exclusive
representative in the Territory with respect to sales of Product pursuant to
this Agreement. All revenues obtained from the sales of Product pursuant to
this Agreement shall be for the account of LifeCell and all accounts
receivable related to such sales shall be accounts receivable of LifeCell.
The Parties agree that LifeCell will record the Net Sales of Product on
LifeCell's financial statements, but that OMP shall be responsible, at its
sole cost and expense, for billing customers and collecting the accounts
receivable from such customers. OMP shall not, without the prior written
approval of LifeCell, sell any Product to customers that are over fifty-nine
(59) days past due on their accounts. OMP will endeavor to include in its
Product invoice a notation to the effect that the Product is distributed by
OMP as distributor for LifeCell.

         3.3 INTENTIONALLY DELETED

         3.4 MICRONIZED ALLODERM-TM- REVENUE ALLOCATION. OMP shall be entitled
to a co-promotion fee for sales of Micronized AlloDerm-TM- according to the
following schedule:

<TABLE>
<CAPTION>

------------------------------------------------------- -----------------------------------------------------
                     Annual Units                         OMP Co-Promotion fee as a Percentage of
          One (1) Unit equals 330 mgs per cc                           Payable Sales
------------------------------------------------------- -----------------------------------------------------
<S>                                                     <C>
                       [***]-[***]                                       [***]%
------------------------------------------------------- -----------------------------------------------------
                     [***] to [***]                                      [***]%
------------------------------------------------------- -----------------------------------------------------
                     [***] and above                                     [***]%
------------------------------------------------------- -----------------------------------------------------

</TABLE>

         The Co-Promotion fee is predicated on a Cost of Goods Sold Percentage
not exceeding [***]%. If the Cost of Goods Sold Percentage exceeds [***]%, then
LifeCell's continuing obligation to supply Product under the terms of this
Agreement shall be limited to the 100,000 Units during the succeeding four
calendar quarters. Further, in this event, the parties agree to use commercially
reasonable efforts to re-negotiate the Co-Promotion Fee payable.

         3.5 MONTHLY PAYMENTS AND REPORTING. On or before the forty-fifth (45th)
day immediately following the last day of each calendar month during the Term,
OMP shall pay to LifeCell the LifeCell Amount less the Hold Back Amount for that
calendar month. OMP shall, on or before the tenth (10th) day of each month,
provide to LifeCell a written report of Net Sales of Products made for the prior
month, setting forth in reasonably sufficient detail the sales price and Unit(s)
of Product ordered and sold and the calculation of the amounts paid to LifeCell
and the co-promotion fees due and retained by OMP, if any. The payment to
LifeCell pursuant to this Section shall be made by check or by wire transfer of
immediately available funds, pursuant to such written wire transfer instructions
as LifeCell may provide to OMP from time to time during the Term. In addition to
any other remedies available to LifeCell arising out of OMP's payment default,
if any payment is more than fifteen days (15) late, OMP shall pay to LifeCell a
late charge on the overdue balance equal to the lesser of (1) 1 1/2% per month
or (ii) the highest rate permitted by applicable law.

                                      -5-

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

         3.6 TRUE-UP OF HOLD BACK AMOUNT. No later than sixty (60) days after
the last day of each Contract Year, OMP shall provide LifeCell with a written
report detailing the Actual Bad Debt incurred by OMP (the "Bad Debt Report").
Such Bad Debt Report shall include, without limitation, information concerning
payment history on applicable OMP customer accounts and a summary of the Actual
Bad Debt amounts (including a calculation of the percentage of Actual Bad Debt
as compared to total gross sales of Product) as of the end of the applicable
Contract Year. If the Actual Bad Debt exceeds the applicable Hold Back Amount,
LifeCell shall, within ten (10) business days after delivery of the Bad Debt
Report, reimburse OMP, in immediately available funds, for the difference
between the Hold Back Amount and the Actual Bad Debt for such Contract Year. If
the Actual Bad Debt does not exceed the Hold Back Amount for such Contract Year,
OMP shall, within ten (10) business days after delivery of the Bad Debt Report,
remit to LifeCell the difference, if any, between the Hold Back Amount and the
Actual Bad Debt. Notwithstanding anything to the contrary contained herein, if
the Hold Back Amount or Actual Bad Debt amount exceeds [***] percent ([***]%)
of the gross sales of Product for any applicable Contract Year, LifeCell may
terminate this Agreement in accordance with Section 13.2.

         3.7 PRODUCT STORAGE, HANDLING, TRANSPORT AND RECORDS. OMP shall store,
handle and transport the Product, and prepare, maintain and retain all records
regarding such matters and OMP's distribution of Product in accordance with (i)
all applicable legal requirements then in effect, including without limitation,
the regulations of the United States Food and Drug Administration ("FDA") and
the United States Department of Health and Human Services (21 C.F.R. Part 1270),
(ii) the Guidelines of the American Association of Tissue Banks and (iii) the
specifications and procedures set forth on Exhibit E annexed hereto and
incorporated herein, as such exhibit may be revised from time to time upon
mutual agreement of the Parties or as required by applicable laws, rules or
regulations.

         3.8 RECORDS; AUDIT RIGHTS. Each party shall keep books and records
sufficient to verify the accuracy and completeness of all activities in
connection with this Agreement, including without limitation, inventory,
shipping and delivery, storing, handling, transport, costs, sales, purchase and
invoice records relating to the Product. Such books and records shall be
preserved for a period not less than ten (10) years after they are created
during and after the Term. Either party may, upon not less than fifteen (15)
business days advance written notice, audit all the books and records of the
other party relating to this Agreement at a single United States location to
verify the accuracy of such party's accounting. Any audit performed pursuant to
this Section 3.8 shall be at expense of the party conducting such audit, unless
it reveals a underpayment or overpayment of five per cent (5%) or more in favor
of the audited party for any Contract year, in which case the audited party
shall reimburse the auditing party for the actual costs of such audit. Such
audit may be performed by any employee of the requesting party as well as by any
attorney or licensed certified public accountant designated by the requesting
party, upon not less than fifteen (15) business days advance notice, during
regular business hours, and in a manner that shall not unreasonably interfere
with such party's normal business operations. Each party shall conduct no more
than one (1) audit during any Contract Year, PROVIDED, HOWEVER, that such audit
shall not be limited to the current Contract Year, but shall be limited to the
period since the completion of the immediately preceding audit, if any. If an
audit reveals any underpayment by OMP to LifeCell, OMP shall pay LifeCell the
amount of such

                                      -6-

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

underpayment within five (5) days of written notification of such
underpayment. If the audit reveals that OMP has made an overpayment to
LifeCell, the amount overpaid will be, at the option of OMP, returned
forthwith to OMP or credited to the next such payment or payments due OMP
from LifeCell.

IV.      MINIMUM SALES AMOUNTS

         4.1 MICRONIZED ALLODERM-TM-. On or before the last day of each
Contract Year set forth in the chart below, OMP shall attain either (i) the
Minimum Annual Sales amount of Micronized AlloDerm-TM- within that specific
Contract Year as set forth in the table below, or (ii) attain the Total
Cumulative Units of Micronized AlloDerm-TM- sold by the last day of the
Contract Year, as set forth in the table below, provided, however, that if
the Date of Commercialization does not occur on or before June 30, 2000, the
amounts set forth in the table below for Year One, Year Two and the Total
Cumulative Units Sold for Years Two, Three, Four and Five will be reduced to
the amount which is prorated on an annual basis for each day after June 30,
2000 until the actual Date of Commercialization in order to take into account
the lesser time available for OMP to achieve the minimum amounts set forth
below.

<TABLE>
<CAPTION>

--------------------------------- --------------------------------------- -------------------------------
         Contract Year                     Minimum Annual Sales                  Total Cumulative
                                                Units Sold                          Units Sold
--------------------------------- --------------------------------------- -------------------------------
<S>                               <C>                                     <C>
            Year One                               [***]                               [***]
--------------------------------- --------------------------------------- -------------------------------
            Year Two                               [***]                               [***]
--------------------------------- --------------------------------------- -------------------------------
           Year Three                              [***]                               [***]
--------------------------------- --------------------------------------- -------------------------------
           Year Four                               [***]                               [***]
--------------------------------- --------------------------------------- -------------------------------
           Year Five                               [***]                               [***]
--------------------------------- --------------------------------------- -------------------------------

</TABLE>

         4.2 FAILURE TO ATTAIN MINIMUM LEVELS. In the event that OMP fails to
meet the obligations set forth in Section 4.1 in any specific Contract Year,
OMP, shall pay to LifeCell in immediately available funds, not later than
thirty (30) after the last day of such Contract Year, [***]% of the
difference between (1) the LifeCell Amount that would have been due to
LifeCell for and as of the last day of such Contract Year had the obligations
set forth in Sections 4.1 been achieved by OMP (the "Minimum Sales Payment")
and (2) any LifeCell Amount actual paid to LifeCell in respect of such
Contract year. In the event that OMP fails to pay to LifeCell an amount equal
to or greater than the Minimum Sales Payment in any Contract Year, LifeCell,
at its sole and exclusive option, may (i) immediately terminate the exclusive
rights granted to OMP in Section 2.1, with such exclusive rights becoming
immediately non-exclusive, or (ii) terminate this Agreement in accordance
with Section 13.2.

         4.3 COMPETITIVE PRODUCTS. If, in any Contract Year, the Net Sales of
Competitive Products offered by OMP exceeds twenty-five percent (25%) of the sum
of total sales of the Product by OMP and the total sales of Competitive
Products offered by OMP, LifeCell, at its

                                      -7-

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

sole and exclusive option, may immediately terminate the exclusive rights
granted to OMP in Section 2.1, with such exclusive rights becoming
immediately non-exclusive.

V.       JOINT MANAGEMENT COMMITTEE

         5.1 STRUCTURE; SCOPE OF RESPONSIBILITY. Within thirty (30) days after
the Effective Date, the Parties shall establish a Joint Management Committee
with an equal number of members from OMP and LifeCell. The Joint Management
Committee will consist of four (4) persons. Each party shall provide the other
party with written notice of the two (2) representatives that such party is
appointing to serve on the Joint Management Committee, and each party shall
retain sole authority to remove its representatives from the Joint Management
Committee and to appoint successors, by providing written notice to the other
party. The Joint Management Committee will facilitate a sharing of information
related to the Product and the respective obligations of the Parties pursuant
to this Agreement. The Joint Management Committee shall have the responsibility
to coordinate the creation of an annual marketing plan and certain activities of
the Parties pursuant to this Agreement, including those related to the
marketing, sales and co-promotion of the Product, and such other matters as the
Parties may mutually agree upon from time to time. Furthermore, the Joint
Management Committee shall use commercially reasonable efforts to set the Price
for the Product.

         5.2 DETERMINATION OF MARKET ENTRY. Within ninety (90) days after the
Effective Date, the Parties shall meet, at a date, time and location to be
designated by the Joint Management Committee, to evaluate the feasibility,
timing and requirements for market entry to introduce Micronized
AlloDerm-TM- into some or all of the countries outside of the United States
that contain significant market opportunities for the sale of the Product.

         5.3 PRODUCT CLASSIFICATION. As of the Effective Date, the FDA has
classified the Product as banked human tissue. The Parties acknowledge and
agree that, under the Federal Food, Drug and Cosmetic Act and regulations
promulgated thereunder, the FDA could at some future time determine that the
Product is a medical device for the intended uses contemplated in this
Agreement rather than human tissue. The Parties also acknowledge and agree that
LifeCell does not warrant that the Product currently meets or in the future will
meet medical device regulatory requirements, including without limitation, that
the Product will not have obtained premarket approval. The Parties further
acknowledge and agree that the FDA's imposition of medical device regulatory
requirements would be substantially more burdensome and costly than the FDA's
human tissue regulatory requirements and that, among other things, the FDA could
require that a party or the Parties take certain actions with respect to the
Product regarding premarket approval, commercial distribution and regulatory
requirements that could have a material impact on the obligations of the Parties
hereunder. In the event that the Joint Management Committee decides to recommend
a change to the regulatory classification, the Joint Management Committee shall
be responsible for recommending the extent of clinical testing and the
regulatory strategy for the Products. Notwithstanding anything contained herein
to the contrary, the Parties acknowledge and agree that LifeCell shall not be
under any obligation under this Agreement to meet or otherwise satisfy the
medical device regulatory requirements. In the event that the FDA undertakes any
action altering the regulatory classification of the Product,

                                      -8-

<PAGE>

and such action has a material adverse effect on the rights or obligations of
the Parties pursuant to this Agreement (including, without limitation, (a)
the commercial viability of any Product and (b) the legal authority or
ability of either party to perform its obligations pursuant to this
Agreement), the Parties' obligations pursuant to this Agreement with respect
to such adversely affected Product shall, in the sole discretion of LifeCell,
be voided or alternatively suspended for so long as the commercial viability
of such Product is affected and the various rights related to such Product
(including those of exclusivity) granted to OMP in this Agreement shall be
extended for a period of time equal to the length of time that such Product
was adversely affected.

VI.      QUALITY ASSURANCE AND ADVERSE EVENT REPORTING.

         6.1 QUALITY COMPLAINTS. Product quality complaints received by OMP
shall be forwarded upon receipt to a quality assurance representative to be
designated by LifeCell. LifeCell retains sole responsibility to investigate
these complaints throughout the Term and to provide OMP with a follow-up report
and required corrective actions, if any, within thirty (30) days of receipt of
such notice.

         6.2 ADVERSE EVENTS. Adverse event reports received by OMP shall be
forwarded upon receipt to LifeCell's designated quality assurance
representative. LifeCell has sole responsibility to fulfill the appropriate
regulatory and reporting requirements related to the adverse event reports
throughout the Term.

         6.3 COMPLAINTS. In the event that LifeCell or OMP receives any
complaint, claim or adverse event report relating to the Product, including
notices from the FDA regarding any alleged regulatory non-compliance of such
Product or the marketing of such Product, such party shall, within ten (10)
days following receipt of such notices, or such shorter period as may be
required by applicable laws, rules or regulations, provide to the other party
all information contained in such complaint, report or notice and any
additional information relating thereto as may reasonably be requested.

         6.4 REGULATORY NOTICES. Each of LifeCell and OMP shall promptly, but
in no event more than five (5) days following the receipt thereof, notify the
other party and provide to such party a copy or transcription, if available,
of any communication received from a regulatory agency relating to the
Product, the marketing thereof, of any matter related thereto.

          6.5 AUDIT OF ADVERSE EVENT REPORTS AND PRODUCT RECALL RECORDS:

         (a)      Upon reasonable notice and during regular business hours, OMP
                  shall make available the records relating to quality
                  complaints referred to in Section 6.1, adverse events referred
                  to in Section 6.2, complaints referred to in 6.3, and
                  regulatory notices referred to in Section 6.4 for audit at
                  LifeCell's expense by independent representatives selected by
                  LifeCell or qualified LifeCell employees to verify compliance
                  with the applicable provisions hereof.

                                      -9-

<PAGE>

         (b)      Upon reasonable notice and during regular business hours,
                  LifeCell shall make available the records relating to quality
                  complaints referred to in Section 6.1, adverse events referred
                  to in Section 6.2, complaints referred to in 6.3, and
                  regulatory notices referred to in Section 6.4 for audit at
                  OMP's expense by independent representatives selected by OMP
                  or qualified OMP employees to verify compliance with the
                  applicable provisions hereof.

VII.     MARKETING, SALES AND CLINICAL TRIALS.

         7.1 LIFECELL RIGHTS AND RESPONSIBILITY. In the event the Joint
Management Committee is unable to agree upon the price of the Product, LifeCell
shall have the sole right to set the price for the Product, and further LifeCell
shall have the sole right to review and approve any preclinical and clinical
activities undertaken by OMP with respect to the Product.

         7.2 OMP RESPONSIBILITY. OMP shall, at its sole cost and expense,
make reasonable efforts to maintain sufficient promotional, marketing, sales,
and distribution capacity to meet the demands of the marketplace for the
Products and to promote and market the Micronized AlloDerm-TM- in the
Territory, including without limitation:

         (a)      the creation, preparation and production of promotional
                  materials related to the Product;

         (b)      the creation and implementation of an advertising campaign to
                  promote the Product;

         (c)      maintaining and compensating a reasonably sufficient number of
                  qualified salespersons to promote and market the Micronized
                  AlloDerm-TM- in the Territory.

         7.3 PRODUCT PACKAGING. Products manufactured and delivered pursuant
to this Agreement shall be labeled in a manner to indicate that the Product
is distributed by OMP for LifeCell and such Product shall be packaged in a
separate trade dress to facilitate product tracking. The Parties agree that
the brand name for the Micronized AlloDerm-TM- shall be "Cymetra-TM-." All
right, title and interest in the name "Cymetra-TM-" shall reside in LifeCell,
and OMP expressly agrees that it neither has nor shall it acquire rights in
the name "Cymetra-TM-" except as expressly set forth in this Agreement.
Within thirty (30) days following the Effective Date, the Parties shall use
diligent commercial efforts to reach mutual agreement on the final packaging
for Product to be distributed pursuant to this Agreement.

         7.4 LIFECELL USE OF MARKETING MATERIALS. OMP, upon LifeCell's request,
shall make the Marketing Materials (as defined in Section 7.5) produced pursuant
to this Article VII available to LifeCell for use in conjunction with the
promotion, marketing, sales and distribution of the Product, and to remove
OMP's name from such Marketing Materials. OMP shall provide the Marketing
Materials to LifeCell at the actual cost of producing such materials, as
incurred by OMP.

                                     -10-

<PAGE>

         7.5 TRADEMARK LICENSES. OMP hereby grants to LifeCell a non-exclusive,
royalty-free right and license to utilize OMP's trademarks, service marks and
trade names as necessary to package and label the Product to be manufactured by
LifeCell pursuant to this Agreement (the "OMP Packaging License"), revocable in
accordance with Section 13.4. LifeCell hereby grants to OMP a non-exclusive,
royalty-free right and license to utilize LifeCell's trademarks, service marks
and trade names as necessary to market, promote, sell and distribute the
Product in the manner contemplated by this Agreement (the "LifeCell Mark
License"), revocable in accordance with Section 13.4. The parties acknowledge
and agree that all right, title and interest in and to any trademarks, service
marks or trade names created for any product or Product developed or invented
hereunder shall reside solely in LifeCell.

         7.6 PRE-PUBLICATION REVIEW OF MARKETING MATERIALS. All Marketing
Materials (as defined below) are expressly subject to pre-publication review and
approval with respect to, but not limited to, content, style, appearance,
composition, timing, and media. Prior to the distribution or publication of any
materials containing any of LifeCell's trademarks, service marks or trade names
("Marketing Materials") OMP shall provide one copy of such Marketing Materials
to LifeCell for final review and approval (Attention: _________, LifeCell
Corporation, One Millennium Way, Branchburg, NJ 08876) at least twenty (20) days
prior to the anticipated publication of such Marketing Materials. LifeCell
agrees to promptly review such Marketing Materials, and LifeCell's failure to
provide written notice of its objection to the use of any Marketing Materials
within twenty (20) business days of their receipt shall constitute LifeCell's
approval of such Marketing Materials. Notwithstanding anything to the contrary
contained herein, OMP shall not use, distribute or publish anything containing
LifeCell's trademarks, service marks or trade names without the express prior
written consent of LifeCell, provided, however that such consent shall be
exercised consistent with this Section 7.6 and not unreasonably, withheld,
conditioned or delayed.

         7.7 MARKETING FOR PERMITTED USES. OMP shall market the Product solely
for those uses for which the Product is permitted to be so marketed pursuant
to FDA and all other applicable legal and regulatory requirements.

VIII.    SUPPLY; FORECASTS; ORDERS AND SHIPPING.

         8.1 AGREE TO SUPPLY. Consistent with the current accepted Forecast
Document (as defined in Section 8.2) and the terms and conditions set forth in
this Agreement, LifeCell shall supply and deliver to OMP Product in such
quantities as OMP requests during the Term of this Agreement, up to the amount
forecasted for such time frame as set forth in the current Forecast Document.
LifeCell shall deliver ordered Product to OMP on the date requested by OMP in
such purchase order, but in no event shall LifeCell be obligated to ship any
Product within less than thirty (30) days from the date of LifeCell's receipt
of a valid written purchase order from OMP. All orders for Product shall be
made pursuant to written purchase orders signed by an authorized representative
of OMP and delivered to LifeCell in accordance with this Article VIII. All
Product received from LifeCell will be held as consigned inventory for
LifeCell. Title to the consigned inventory will remain with LifeCell until the
time that OMP has delivered the Product to the customer and the invoice
therefor, at which time title to such Product shall pass to the customer.

                                     -11-

<PAGE>

OMP will return to LifeCell for disposal any expired Product held as consigned
inventory by OMP.

         8.2 FORECASTS. Every thirty (30) days during the Term, OMP shall
provide LifeCell with a good faith non-binding running estimate of the
quantity of Product OMP reasonably estimates OMP will order and sell during
each of the next twelve (12) months (but not extending beyond the Term) (the
"Forecast Document"). OMP shall provide its initial forecast within thirty
(30) days after the Effective Date. LifeCell shall have ten (10) days to
review the Forecast Document. If, in LifeCell's good faith judgment, LifeCell
will be unable to meet the amounts set forth in the Forecast Document,
LifeCell shall provide written notice thereof to OMP, and the Parties shall
negotiate in good faith an acceptable amount. If despite reasonable efforts,
LifeCell is unable to supply adequate Product to meet the demands of OMP (as
set forth in the Forecast Document), LifeCell and any third party licensee of
the Product, then LifeCell shall use commercially reasonable efforts to
devise an allocation system of existing supply to be reviewed monthly. If the
Parties are unable to agree upon an allocation of available product, the
matter shall be resolved in accordance with Section XIV.

         8.3 ORDERS. Each OMP purchase order shall be in a form compatible
with LifeCell's business form requirements and shall be subject to the terms
and conditions of this Agreement. No printed term or provision contained in
any OMP form or any LifeCell form which is inconsistent with or in addition
to the terms of this Agreement shall be effective to alter the terms of this
Agreement in any way unless agreed to in writing by both Parties. Each
purchase order shall be subject to this Agreement and shall incorporate the
terms and conditions of this Agreement. Each purchase order shall include at
least the following information: the date of the order; the specific Product
ordered; the quantity of each Product ordered; the price of the Product; and
a delivery date for the order.

         8.4 CANCELLATION OF ORDERS. OMP may, at no cost, cancel any purchase
order at any time up to twenty (20) days prior to the shipping date set forth on
such purchase order and may reschedule any order at any time up to twenty (20)
days prior to the shipping date set forth on such purchase order.

         8.5 DELIVERY. LifeCell shall use commercially reasonable efforts to
ship orders according to the delivery date specified in each purchase order
accepted by LifeCell. Notwithstanding the foregoing, LifeCell shall not be
responsible for any delay in filling any purchase order due to a force majeure
condition as set forth in Section 15.3.

         8.6 SHIPPING. LifeCell shall ship Products, F.O.B. destination, to
OMP's warehouse or such other OMP business location in the United States of
America designated by OMP, in a final, packaged form, ready for immediately
delivery to customers.

         8.7 INSPECTION; ACCEPTANCE. OMP shall have the right to inspect the
Product prior to sale to customers and shall notify LifeCell in writing of
OMP's rejection of any Product due to the failure of the Product to meet
Specifications. Such written notification by OMP shall include a detailed
description of the test(s) that OMP performed on the Product and the results
of such test(s).

                                     -12-

<PAGE>

LifeCell maintains the right to perform its own tests on Product rejected by
OMP to determine if the Product meets Specifications. In the event that
LifeCell's inspection verifies that the rejected Products failed to meet the
applicable Specifications, LifeCell shall, in its sole discretion, either
repair or replace all Product properly rejected under this Section 8.7.
LifeCell shall bear the cost of shipping rejected Product back to LifeCell,
as well as bear the cost of shipping replacement Product to OMP under this
Section 8.7. In the event that LifeCell's inspection indicates that the
Product does meet the applicable Specifications, LifeCell shall provide the
results of its tests to OMP. In the event that the Parties are unable to
reach agreement concerning Product rejected by OMP and which Product
LifeCell's tests indicate conforms to applicable specifications, either party
may invoke the dispute resolution procedure set forth in Article XIV.

IX.      REPRESENTATIONS AND WARRANTIES; RELATED MATTERS; LIMITATION OF
         LIABILITY

         9.1 MUTUAL REPRESENTATIONS AND WARRANTIES. Each of the Parties
represents and warrants to the other that:

         (a)      it is duly organized, validly existing and in good standing in
                  accordance with the laws of its jurisdiction of organization;

         (b)      it has all requisite legal and corporate power and authority
                  to enter into and perform its obligations under this
                  Agreement;

         (c)      it has duly authorized the entry into and performance of its
                  obligations under this Agreement by all requisite corporate
                  actions;

         (d)      when executed by each of the Parties hereto, this Agreement
                  shall be a legal, valid and binding obligation of such party
                  enforceable in accordance with its terms, subject to
                  bankruptcy, insolvency and similar laws affecting creditors'
                  rights generally and general principles of equity;

         (e)      its execution and delivery and performance of its obligations
                  under this Agreement do not breach, violate, conflict with or
                  contravene in any material respect (i) its organizational
                  documents, (ii) any laws, rules, regulations, orders,
                  judgments or decrees applicable to or binding upon it or its
                  property, or (iii) any other agreement, instrument, mortgage,
                  indenture, contract, license or other document to which it is
                  a party or by which it is bound;

         (f)      it has obtained all governmental and third party consents and
                  made all filings and notices required in connection with its
                  execution, delivery and performance of this Agreement, and all
                  such consents, filings and notices remain in full force and
                  effect; and

         (g)      it will comply in all material respects with all applicable
                  laws, rules and regulations in the conduct of its
                  responsibilities and activities under this Agreement.

         9.2 ADDITIONAL LIFECELL REPRESENTATIONS AND WARRANTIES. LifeCell
represents and warrants to OMP that:

                                     -13-

<PAGE>

         (a)      all Product will conform in all material respects to the
                  Specifications;

         (b)      LifeCell is and will remain in substantial compliance
                  with good manufacturing practices;

         (c)      LifeCell has, and throughout the Term at all times shall
                  maintain, at LifeCell's sole expense, sufficient right, title
                  and interest in all Intellectual Property (other than the OMP
                  Packaging License and other Intellectual Property owned by
                  OMP) necessary to produce and license the Product for sale in
                  the Territory contemplated by this Agreement;

         (d)      LifeCell holds each item of registered or registrable
                  Intellectual Property (including, without limitation, patents,
                  trademarks, trade names, and applications for any of the
                  foregoing (including the status of such applications and any
                  rejections or challenges thereof)) listed on Exhibit A;

         (e)      there are no interference, opposition or cancellation
                  proceedings pending or threatened against any of the
                  Intellectual Property listed on Exhibit A;

         (f)      no claim, suit or action to which LifeCell is a party or which
                  is known to LifeCell is pending or, to LifeCell's knowledge
                  after due inquiry, threatened alleging that any Product is
                  infringing or would infringe upon the Intellectual Property
                  rights of others; and

         (g)      the Product and the licenses and rights granted or purported
                  to be granted to OMP pursuant to this Agreement with respect
                  thereto do not infringe, violate or otherwise impair any
                  Intellectual Property right or any other proprietary right of
                  any third party in the United States.

         9.3 ADDITIONAL OMP REPRESENTATIONS AND WARRANTIES. OMP represents and
warrants to LifeCell that:

         (a)      the OMP Packaging License includes all the Intellectual
                  Property rights necessary for LifeCell to produce the
                  packaging and labeling required by this Agreement;

         (b)      it will store, handle and transport the Products, and prepare,
                  maintain and retain all records regarding such matters and its
                  distribution of Product in accordance with (i) all applicable
                  legal requirements then in effect, including without
                  limitation, the regulations of the FDA and the United States
                  Department of Health and Human Services (21 C.F.R. Part 1270),
                  (ii) the Guidelines of the American Association of Tissue
                  Banks and (iii) the specifications and procedures set forth on
                  Exhibit E annexed hereto and incorporated herein, as such
                  exhibit may be revised from time to time upon mutual agreement
                  of the Parties and in compliance with appropriate state
                  statutes and regulations.

         9.4 DISCLAIMER OF DAMAGES. WITH THE EXCEPTION OF THE INDEMNIFICATION
OBLIGATIONS SET FORTH IN ARTICLE X, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO
THE OTHER PARTY FOR ANY SPECIAL, COLLATERAL, INDIRECT, EXEMPLARY, INCIDENTAL OR
CONSEQUENTIAL

                                    -14-

<PAGE>

DAMAGES, INCLUDING BUT NOT LIMITED TO, LOSS OF GOODWILL, LOSS OF PROFITS, OR
LOSS OF USE, FOR BREACH OF ANY OF THE PROVISIONS OF THIS AGREEMENT,
REGARDLESS OF WHETHER SUCH LIABILITY IS BASED ON BREACH OF CONTRACT, TORT,
STRICT LIABILITY OR OTHERWISE, AND EVEN IF ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES.

X.       INDEMNIFICATION

         10.1 SCOPE OF INDEMNITY. Each party (the "Indemnifying Party")
agrees to indemnify, defend and hold the other party and any of its parent
companies and Affiliates, and the present and former officers, members,
shareholders, directors, employees, representatives, attorneys, insurers and
agents of any of these, and their successors, heirs and assigns (each, an
"Indemnified Party") harmless from and against any and all losses,
liabilities, claims, costs, damages and expenses (including, without
limitation, fines, forfeitures, attorneys' fees, disbursements and
administrative or court costs) arising directly or indirectly out of any
breach or alleged breach of its representations and warranties in this
Agreement. Each party further agrees to indemnify defend and hold the other
party, its parent, subsidiaries and affiliates, and each of their respective
present and former officers, members, shareholders, directors, employees,
representatives, attorneys, agents, successors heirs and assigns (each, an
"Indemnified Party"), harmless from any and all losses, liabilities, claims,
costs, damages and expenses (including, without limitation, fines,
forfeitures, attorneys' fees, disbursements and administrative or court
costs) arising directly or indirectly out of (a) the handling or sale of the
Product by the Indemnifying Party and (b) the manufacture of the Product by
the Indemnifying Party. LifeCell further agrees to indemnify defend and hold
OMP, its parent, subsidiaries and affiliates, and each of their respective
present and former officers, members, shareholders, directors, employees,
representatives, attorneys, agents, successors heirs and assigns (each, an
"Indemnified Party"), harmless from any and all losses, liabilities, claims,
costs, damages and expenses (including, without limitation, fines,
forfeitures, attorneys' fees, disbursements and administrative or court
costs) arising directly or indirectly out of the use of the Product by third
parties, other than those that arise out of OMP's breach of its obligations
under Section 3.7 of this Agreement or any material misprepresentation
relating to any Product made by OMP.

         10.2 PROCESS. Any Indemnified Party seeking indemnification shall
notify the Indemnifying Party of the indemnified claim or action in writing
within a reasonably prompt time. Upon receipt of notice of the assertion of a
claim, the Indemnifying Party shall employ counsel reasonably acceptable to the
Indemnified Party and shall assume defense of the claim. The Indemnified Party
shall have the right to employ separate counsel and to participate in (but not
control) any such defense. The fees and expenses of such separate counsel shall
be at the expense of the Indemnified Party unless (a) the Indemnified Party has
been given a formal opinion by its counsel that there is a conflict of interest
between it and the Indemnifying Party, or (b) the Indemnifying Party has not in
fact employed counsel to assume defense of the action within a reasonable time
following receipt of the notice given pursuant to this Agreement, in each of
which cases the fees and expenses of such counsel shall be at the expense of the
Indemnifying Party. The Indemnifying Party agrees that it will not consent to
the entry of any judgment or enter into any settlement which does not include as
an unconditional term thereof

                                     -15-

<PAGE>

the giving by the claimant or plaintiff to the Indemnified Party a release
from all liability with respect to the claim. Each Indemnified Party shall
reasonably cooperate in the defense of any claim for which indemnification is
required and shall furnish such records, information, testimony and attend
such conferences, discovery proceedings, hearings, trials and appeal as may
reasonably requested by the Indemnifying Party.

         10.3 IP INFRINGEMENT. If any claim involving infringement, violation
or impairment of any kind of Intellectual Property for which LifeCell is
obligated to indemnify OMP pursuant to this Article X is resolved in a manner
that precludes LifeCell from granting any right included in the Intellectual
Property, LifeCell will, at LifeCell's expense:

                  (a)      procure such license as is necessary for OMP's past
                           rights and future rights to continue to exercise all
                           rights granted with respect to the Product under
                           this Agreement;

                  (b)      replace or modify the allegedly infringing item(s) to
                           avoid the infringement, without materially impairing
                           performance or compliance with the Product's
                           specifications to OMP's reasonable satisfaction, or

                  (c)      if neither the procuring of such a license nor the
                           replacement or modification as above-described are
                           economically practicable, accept return of all the
                           Product delivered to OMP which have not been sold
                           to customers and refund OMP all its necessary and
                           reasonable costs incurred as a result of LifeCell's
                           inability to procure the past rights for OMP to
                           continue to exercise all rights granted herein.

         10.4 RIGHT TO SET-OFF. Each Indemnified Party shall be entitled to
offset against any obligations owed by such party to the Indemnifying Party
the sum of all Indemnifiable Damages that such Indemnified Party is entitled
to pursuant to this Article X.

         10.5 INSURANCE. Each party shall maintain at its expense commercial
general liability insurance in a principal amount of not less than the
coverage generally maintained by companies of similar size in its industry.
Each party shall also maintain a product liability policy relating to any use
of the Product at any time after the date of this Agreement with coverage of
not less than One Million Dollars ($1,000,000) per occurrence and Ten Million
Dollars ($10,000,000) in the aggregate. Each of the policies required under
this Section 10.5 and maintained by any party shall name the other party as
an additional insured and require the insurer to provide at least thirty (30)
days written notice to such other party before any cancellation or material
change to the limits, deductibles or terms of such policies. Within thirty
(30) days after the date of this Agreement, each party shall furnish to the
other party certificates evidencing its insurance, such other party's
designation as additional insured, and such notice requirement. Any party may
elect to suspend its performance under this Agreement until any insurance
required to be maintained by the other party is in place and such
certificates of coverage are provided.

                                     -16-

<PAGE>

XI.      CONFIDENTIAL INFORMATION

         11.1 CONFIDENTIAL INFORMATION. Each party acknowledges that it and
its employees or agents may, in the course of this Agreement, be exposed to
or acquire information which is proprietary or confidential to the other
party ("Confidential Information"). Confidential Information hereunder shall
include, if disclosed orally and such disclosure contains an oral statement
that the information being disclosed is confidential or proprietary (provided
such statement is followed by a writing delivered to the receiving party
within thirty (30) days of the initial disclosure which indicates the date of
disclosure and a non-confidential description of the Confidential Information
disclosed, or if disclosed in writing or visually, a legend or some other
clear written indication that the information disclosed is confidential or
proprietary: (a) marketing, sales, financial, scientific, and other
non-public and/or proprietary information concerning the Product, projects,
business and operations of such party and its Affiliates including the
manufacture, use, or sale of the Product; (b) any technical information,
design, process, procedure, formula, improvement, and other data relating to
the development or production of the Product; and (c) the terms and
conditions of this Agreement. Confidential Information shall not include any
information that is: (a) generally known or available to the public through
no act of the receiving party, (b) already known to the receiving party at
the time of receiving the Confidential Information, or (c) furnished to the
receiving party by a third party with the right to do so. In the event that
any disclosure of Confidential Information is required by a governmental
authority or by order of a court of competent jurisdiction, the disclosing
party shall, prior to disclosure and as soon as practicable by the best
available means, notify the other party thereof in an effort to permit the
disclosing party adequate opportunity to object to the disclosure order or
take other action to preserve the confidentiality of the Confidential
Information.

         11.2 NO ADDITIONAL RIGHTS. The furnishing of Confidential
Information by one party to the other shall not constitute any grant, option
or license to the other under any patent or other rights now or hereafter
held by the furnishing party.

         11.3 LENGTH OF SURVIVAL. The provisions of this Article XI shall
survive termination of this Agreement and continue for a period of three (3)
years.

XII.     PRODUCT RECALLS; COMPLAINTS AND REGULATORY NOTICES

         12.1 RESPONSIBILITY FOR RECALL. In the event any Product must be
recalled from the channel of distribution by reason of failure to meet any
requirements of law or otherwise, OMP shall have the sole responsibility to
effect the recall. LifeCell shall use its best efforts to cooperate with OMP in
implementing any such recalls to the extent such cooperation is necessary to
effect the recall.

         12.2 RESPONSIBILITY FOR REIMBURSEMENT. In the event the recall results
from or is caused by an act or omission by OMP, OMP shall reimburse LifeCell for
any costs and/or expenses reasonably expended by LifeCell as a consequence of
the recall. Without limiting the general nature of the foregoing, OMP shall bear
the cost of any Product involved in such recall. In the event the recall
results from or is caused by an act or omission by LifeCell, LifeCell shall

                                     -17-

<PAGE>

reimburse OMP for any costs and/or expenses reasonably expended by OMP as a
consequence of the recall. Without limiting the general nature of the
foregoing, LifeCell will provide replacement Product for recalled Product
and for any Product that cannot be shipped due to the condition requiring
the recall.

XIII.     TERM; RENEWAL; TERMINATION

         13.1 TERM. This Agreement shall become effective on the Effective
Date and shall continue for a period of five (5) years (the "Initial Term"),
unless this Agreement is otherwise (a) terminated as provided in this
Agreement, or (b) extended by mutual agreement of the Parties in a written
instrument executed in conformance with the procedure for amending this
Agreement. If OMP meets or exceeds the minimum sales levels described in
Section 4.1, or alternatively, makes the payments to LifeCell described in
Section 4.2 in a timely manner, and is not otherwise in default of its
obligations hereunder, then OMP shall have the right to renew the Agreement
for an additional five (5) year term (a "Renewal Term") by notifying LifeCell
of its intent to renew the Agreement, in writing, at least one hundred and
eighty (180) days prior to the expiration of the Initial Term, in which case
the Minimum Annual Sales Amounts set forth in Article IV shall be increased
by [***] percent ([***]%) annually for the Term. The Initial Term, any mutually
agreed upon extensions, and the Renewal Term(s), if any, shall constitute the
"Term" of this Agreement.

         13.2 TERMINATION FOR CAUSE. Either party has the right, but not the
obligation, to terminate this Agreement in the event of a material breach of
this Agreement by the other party, unless such breach is cured within thirty
(30) days of receipt of written notice of such breach.

         13.3 TERMINATION DUE TO INSOLVENCY OR BANKRUPTCY. Either party may
terminate this Agreement upon thirty (30) days advance notice if the other
party is declared insolvent or bankrupt by a court of competent jurisdiction,
or a voluntary petition of bankruptcy is filed in any court of competent
jurisdiction by such party, or such party makes or executes an assignment for
the benefit of creditors.

         13.4 EVENTS UPON TERMINATION. Upon the termination, expiration or
cancellation of this Agreement, all rights granted by LifeCell to OMP with
respect to the Product or Improvement shall cease, other than the right to
complete the sale of Product then lawfully in its possession. Each party
will remain obligated to pay outstanding amounts due prior to the date of
termination. Each party will promptly return to the other party or destroy
all copies of any Confidential Information, including all notes, abstracts,
and other documents that contain Confidential Information, and will provide
to the other party a written certification from an officer certifying how
such Confidential Information was disposed. The OMP Packaging License and the
LifeCell Mark License shall expire upon the expiration, termination or
cancellation of this Agreement.

         13.5 SURVIVAL OF TERMINATION. The obligations of the parties under
Articles I, IX, X, XI, XIV and XV shall survive any such expiration,
termination or cancellation, subject to any limitation specified in such
Article and Section.

                                     -18-

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

XIV.      ALTERNATIVE DISPUTE RESOLUTION

       14.1 DISPUTE RESOLUTION. In order to attempt to resolve any dispute
between the Parties hereunder, and except as otherwise specifically provided
herein to the contrary, as a condition precedent to the non-breaching party
terminating this Agreement under Section 13.2 or as otherwise provided in
this Agreement, or filing a suit, instituting a proceeding or seeking other
governmental resolution in connection with this Agreement, the Parties, with
the help and assistance of the Joint Management Committee, will attempt to
reach a mutually agreeable resolution of the dispute through best efforts
negotiation for a minimum of thirty (30) business days. If the Parties are
unable to reach a mutually agreeable resolution within such thirty (30)
business days, then the Parties shall submit the dispute to a non-binding
mediation for a minimum of an additional sixty (60) business days, utilizing
a single mediator who is a retired judge mutually agreed upon by the Parties.
If the Parties are unable to reach a mutually agreeable resolution within
such ninety (90) business days, either party may exercise its rights
hereunder in the manner selected by such party in order to resolve the
dispute.

XV.       MISCELLANEOUS

         15.1 PREAMBLE; RECITALS. The Preamble and Recitals set forth above
are intended to be an integral part of this Agreement, and the Preamble and
Recitals (including the definitions set forth therein) are hereby
incorporated by reference.

         15.2 NOTICES. Any notices required or permitted to be given
hereunder shall be delivered by personal delivery, overnight commercial
courier or by certified mail, return receipt requested, at the address of the
parties specified below, and shall be effective upon receipt. Either party
may at any time designate another person or address for the receipt of notice
by notifying the other party in accordance with this Section 15.2.

         If to LifeCell:                    If to OMP:

         LifeCell                           Obagi Medical Products, Inc.
         One Millenium Way                  310 Golden Shore
         Branchburg, NJ 08876               Long Beach, CA 90802
         Attn: Paul Thomas, CEO             Attn: Philip Rose

                                     -19-

<PAGE>

         With a copy to:

         Lowenstein Sandler, PC             Michael Best & Friedrich LLP
         50 Division Street                 One South Pinckney St, #700
         Somerville, NJ  08876              Madison, WI  53703
         Attn:  Steven B. Fuerst, Esq.      Attn:  Tod B. Linstroth, Esq.

         15.3 FORCE MAJEURE. Neither party shall be deemed in default or
otherwise liable under this Agreement due to its inability to perform its
obligations by reason of any fire, earthquake, flood, substantial snowstorm,
epidemic, accident, explosion, casualty, strike, lockout, labor controversy,
riot, civil disturbance, act of public enemy, embargo, war, act of God, or
any municipal, county, state or national ordinance or law, or any executive,
administrative or judicial order (which order is not the result of any act or
omission which would constitute a default hereunder), or any failure or delay
of any transportation, power, or communications system or any other or
similar cause beyond that party's reasonable control.

         15.4 GOVERNING LAW. This Agreement and all matters or issues related
this Agreement shall be governed by the laws of the State of New Jersey
without regard to its choice of law or conflict of laws rules.

         15.5 ASSIGNMENT. Neither party shall sell, assign, mortgage or
otherwise transfer any of its rights or obligations under this Agreement
without the consent of the other party, such consent not to be unreasonably
withheld, conditioned or delayed, nor shall any of said rights or obligations
be assigned or transferred by operation of law or otherwise without such
consent. Notwithstanding the foregoing, either party may assign this
Agreement in connection with a sale of all or substantially all of its assets
or equity interests, or to any Affiliate. In the event of any permitted
assignment or transfer, the approved assignee shall agree to accept and abide
by all of the terms and conditions of this Agreement.

         15.6 RELATIONSHIP OF PARTIES: NO JOINT VENTURE. Neither this
Agreement nor the cooperation of the parties contemplated under this
Agreement shall be deemed or construed to create any partnership, joint
venture or other business entity between OMP and LifeCell.

         15.7 SEVERABILITY. The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability
of any other provision of this Agreement. In the event that any provision of
this Agreement is determined to be invalid, unenforceable or otherwise
illegal, such provision shall be deemed restated, in accordance with
applicable law, to reflect as nearly as possible the original intentions of
the parties, and the remainder of this Agreement shall remain in full force
and effect.

         15.8 WAIVER. No term or condition of this Agreement shall be deemed
waived, and no breach shall be deemed excused, unless such waiver or excuse
is in writing and is executed by the party against whom such waiver or excuse
is claimed.

                                     -20-

<PAGE>

         15.9 ENTIRE AGREEMENT; AMENDMENTS. This Agreement, including all
Exhibits, contains the entire agreement and understanding between the parties
with regard to the subject matter hereof, and supersedes all prior and
contemporaneous oral or written agreements and representations. Any amendment
of this Agreement shall be in writing and signed by both parties.

         15.10 COMMUNICATIONS. Each party agrees that it shall not make any
public announcement regarding the cooperative relationship described in this
Agreement without the prior approval of the other, both as to timing and
substance, such approval not to be unreasonably withheld.

         15.11 COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall constitute an original and all of which
taken together shall constitute one and the same Agreement.

                                     -21-

<PAGE>

          IN WITNESS WHEREOF, the parties, intending to be legally bound, as
described in the Preamble, have caused this Agreement to be executed by their
authorized representatives.

LifeCell Corporation                        Obagi Medical Products, Inc.

By:    /s/ P. Thomas                        By: /s/ Phillip Rose
   --------------------------------             -------------------------------
Name:  Paul G. Thomas                       Name: Phillip J. Rose
     ------------------------------               -----------------------------
Title: President & CEO                      Title: President & CEO
      -----------------------------                ----------------------------

                                      -23-

<PAGE>

                                    EXHIBIT A

               SCHEDULE OF INTELLECTUAL PROPERTY OWNED BY LIFECELL

U.S. Patent No. 5,336,616

         "Method for Processing and Preserving Collagen-Based Tissues for
         Transplantation" Corresponding Applications filed or issued: AU, CA,
         EP, JP

U.S. Application No. 08/759,801

         "Method for Processing and Preserving Collagen-Based Tissues for
         Transplantation"

U.S. Application No. 09/207,179

         "Reconstituted Skin"

PCT Application No. US99/038667

         "Method for Processing and Preserving Collagen-Based Tissues"

PCT Application No. US99/13861

         "Particulate Acellular Tissue Matrix" (Micronized
         ALLODERM-Registered Trademark-)

                               TRADEMARK PORTFOLIO

LIFECELL-Registered Trademark-

         Registration No. 1,475,428

ALLODERM-Registered Trademark-

         Registration No. 1,782,561

                     TRADEMARK PORTFOLIO UNDER CONSIDERATION

MICRONIZED ALLODERM-TM-

                                   CYMETRA-TM-

                                      A-1

<PAGE>

                                      EXHIBIT B

--------------------------------------------------------------------------------
                 LIFECELL CORPORATION, THE WOODLANDS, TEXAS
                         FINISHED GOOD SPECIFICATION                   100A0008
MICRONIZED ALLODERM, 330 MG VIAL                                         Rev. A
LifeCell Part No.: 602001                                           Page 1 of 2
--------------------------------------------------------------------------------

1     PURPOSE
      This specification describes the required characteristics of Micronized
      AlloDerm, requirements for raw materials, and, by reference, the process
      required to produce, inspect, ship, and track individual pieces to the
      customer.

2     APPLICABLE DOCUMENTS
      The following documents are referenced in this specification by title:
           AATB, STANDARDS FOR TISSUE BANKING
           FDA INTERIM RULE, CFR 1270

      2.1  Design Documents
           111A0001    SKIN, HUMAN, CADAVER

      2.2  Manufacturing Documents
           002S0014    PACKAGING FOR MICRONIZED ALLODERM
           100S0008    MICRONIZED ALLODERM

      2.3  Quality Assurance Documents
           001S0002    ALLODERM TRACKING
           001S0054    QA RELEASE FOR MICRONIZED ALLODERM

3     DESCRIPTION
      Micronized AlloDerm is a freeze-dried acellular matrix derived from
      papillary and reticular human dermis and is characterized by the
      following:

      a    Dermal and epidermal cells removed, evidenced by histological
           analysis

      b    Collagen bundles are intact, evidenced by electron microscopic
           analysis

      c    Absence of commensal and pathogenic microorganisms per
           microbiological testing (method CFR 610.12/Viromed or equivalent)

      d    Macroscopic appearance should be white to buff-colored and not
           exhibit consolidated aggregates that cannot be broken up when the
           dry sample is agitated

      e    Residual moisture content of LESS THAN OR EQUAL TO 5%, evidenced by
           residual moisture analysis

4     QUALITY ASSURANCE

      4.1  TESTING
           All tissue processed for Micronized AlloDerm shall be tested and
           accepted/rejected per QA Release for Micronized AlloDerm (001S0054).

      4.2  TRACKING
           Micronized AlloDerm supplied by LifeCell for transplantation or
           testing shall be tracked per AlloDerm Tracking in accordance with FDA
           Interim Rule CFR 1270.

<PAGE>

                                                                     Page 2 of 2

5     PACKAGING/LABELING

      5.1  PACKAGING
           Each dose of Micronized AlloDerm shall be packaged in an autoclaved
           siliconized glass vial with a minimum of 330 mg of dry product per
           dose.

      5.2  LABELING
           All package labels (excluding marketing overlabels) shall be capable
           of withstanding temperatures of -35DEG.C to +40DEG.C without adverse
           effects on the printing or loss of label adhesion to the vials.

6     STORAGE
      All Micronized AlloDerm which meets the requirements of the QA Release
      for Micronized AlloDerm, and is hence accepted for Finished Goods, shall
      be stored in a restricted, temperature-controlled environment (1DEG.C to
      10DEG.C) until the time of distribution. All Micronized AlloDerm, which
      does not meet the requirements, and is hence rejected, shall be stored in
      a separate temperature-controlled environment until such time that the
      disposition of such tissue is determined.

<PAGE>

                     FINAL OBAGI CUSTOMER LIST 2/9/00  EXHIBIT C

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
              TNX  CUST                SUM OF                                                                                  O
  #  CUST ID  YR   TYPE  PECIA  TER    TNXAMT           NAME                     ADDRESS                CITY      STATE  ZIP   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                         <C>           <C>   <C>   <C>
  1     4528   99  O     PL     101  $                                           [***]                                          O
  2     3689   99  O     PL     101  $                                                                                          O
  3     4729   99  O     PL     101  $                                                                                          O
  4     4391   99  O     PL     101  $                                                                                          O
  5     4298   99  O     PL     101  $                                                                                          O
  6     4043   99  O     PL     101  $                                                                                          O
  7     4543   99  O     PL     101  $                                                                                          O
  8     3832   99  O     PL     101  $                                                                                          O
  9     4403   99  O     PL     101  $                                                                                          O
 10     3957   99  O     PL     101  $                                                                                          O
 11     4397   99  O     PL     101  $                                                                                          O
 12     4233   99  O     PL     101  $                                                                                          O
 13     3140   99  O     PL     101  $                                                                                          O
 14     1387   99  O     PL     101  $                                                                                          O
 15     3379   99  O     PL     101  $                                                                                          O
 16     4579   99  O     PL     101  $                                                                                          O
 17     3218   99  O     PL     101  $                                                                                          O
 18     3347   99  O     PL     101  $                                                                                          O
 19     3052   99  O     PL     101  $                                                                                          O
 20     3245   99  O     PL     101  $                                                                                          O
 21     4639   99  O     PL     101  $                                                                                          O
 22     4000   99  O     PL     101  $                                                                                          O
 23     3599   99  O     PL     101  $                                                                                          O
 24     3165   99  O     PL     101  $                                                                                          O
 25     3706   99  O     PL     101  $                                                                                          O
 26     4395   99  O     PL     101  $                                                                                          O
 27     3973   99  O     PL     101  $                                                                                          O
 28     3902   99  O     PL     101  $                                                                                          O
 29     4488   99  O     PL     101  $                                                                                          O
 30     3870   99  O     PL     101  $                                                                                          O
 31     4324   99  O     PL     101  $                                                                                          O
 32     3161   99  O     PL     102  $                                                                                          O
 33     4779   00  O     PL     102                                                                                             O
 34     4011   99  O     PL     102  $                                                                                          O
 35     4793   00  O     PL     102                                                                                             O
 36     3110   99  O     PL     102  $                                                                                          O
 37     3617   99  O     PL     102  $                                                                                          O
 38     4836   00  O     PL     102                                                                                             O
 39     3146   99  O     PL     102  $                                                                                          O
 40     4792   00  O     PL     103                                                                                             O
 41     2510   99  O     PL     103  $                                                                                          O
</TABLE>

***  Material has been omitted pursuant to a request for confidential
     treatment and such material has been filed separately with the
     Securities and Exchange Commission.

<PAGE>

                                     FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                  O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS                CITY      STATE  ZIP   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                         <C>           <C>   <C>   <C>
 42   3732      99   O     PL   103   $                                            [***]               [***]                    0
 43   3564      99   O     PL   104   $                                                                                         0
 44   3964      99   O     PL   104   $                                                                                         0
 45   2951      99   O     PL   104   $                                                                                         0
 46   4037      99   O     PL   104   $                                                                                         0
 47   4612      99   O     PL   104   $                                                                                         0
 48   3448      99   O     PL   104   $                                                                                         0
 49   4451      99   O     PL   104   $                                                                                         0
 50   4565      99   O     PL   104   $                                                                                         0
 51   3071      99   O     PL   104   $                                                                                         0
 52   4578      99   O     PL   104   $                                                                                         0
 53   2889      99   O     PL   104   $                                                                                         0
 54   4704      99   O     PL   105   $                                                                                         0
 55   4359      99   O     PL   105   $                                                                                         0
 56   3049      99   O     PL   105   $                                                                                         0
 57   4004      99   O     PL   105   $                                                                                         0
 58   3655      99   O     PL   105   $                                                                                         0
 59   4439      99   O     PL   105   $                                                                                         0
 60   4036      99   O     PL   105   $                                                                                         0
 61   4412      99   O     PL   105   $                                                                                         0
 62   4056      99   O     PL   105   $                                                                                         0
 63   1413      99   O     PL   105   $                                                                                         0
 64   4722      99   O     PL   105   $                                                                                         0
 65   2556      99   O     PL   105   $                                                                                         0
 66   3887      99   O     PL   105   $                                                                                         0
 67   4159      99   O     PL   105   $                                                                                         0
 68   2962      99   O     PL   105   $                                                                                         0
 69   4082      99   O     PL   105   $                                                                                         0
 70   2887      99   O     PL   105   $                                                                                         0
 71   4363      99   O     PL   105   $                                                                                         0
 72   1467      99   O     PL   105   $                                                                                         0
 73   3639      99   O     PL   105   $                                                                                         0
 74   4060      99   O     PL   105   $                                                                                         0
 75   4156      99   O     PL   105   $                                                                                         0
 76   4510      99   O     PL   105   $                                                                                         0
 77   2936      99   O     PL   105   $                                                                                         0
 78   4350      99   O     PL   105   $                                                                                         0
 79   3770      99   O     PL   105   $                                                                                         0
 80   4126      99   O     PL   106   $                                                                                         0
 81   3882      99   O     PL   106   $                                                                                         0
 82   2968      99   O     PL   107   $                                                                                         0
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                  O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS                CITY      STATE  ZIP   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                         <C>           <C>   <C>   <C>
 83   4854      99   O     PL   107   $                                            [***]               [***]                    0
 84   4549      99   O     PL   107   $                                                                                         0
 85   2623      99   O     PL   108   $                                                                                         0
 86   2882      99   O     PL   108   $                                                                                         0
 87   4311      99   O     PL   108   $                                                                                         0
 88   2988      99   O     PL   108   $                                                                                         0
 89   3585      99   O     PL   108   $                                                                                         0
 90   4725      99   O     PL   108   $                                                                                         0
 91   4758      99   O     PL   108   $                                                                                         0
 92   2997      99   O     PL   108   $                                                                                         0
 93   3357      99   O     PL   108   $                                                                                         0
 94   2009      99   O     PL   108   $                                                                                         0
 95   1341      99   O     PL   108   $                                                                                         0
 96   4422      99   O     PL   108   $                                                                                         0
 97   4585      99   O     PL   108   $                                                                                         0
 98   2910      99   O     PL   108   $                                                                                         0
 99   3002      99   O     PL   108   $                                                                                         0
100   4306      99   O     PL   108   $                                                                                         0
101   3802      99   O     PL   108   $                                                                                         0
102   3394      99   O     PL   108   $                                                                                         0
103   3374      99   O     PL   108   $                                                                                         0
104   3145      99   O     PL   108   $                                                                                         0
105   4356      99   O     PL   108   $                                                                                         0
106   4194      99   O     PL   108   $                                                                                         0
107   4234      99   O     PL   109   $                                                                                         0
108   3124      99   O     PL   109   $                                                                                         0
109   4512      99   O     PL   109   $                                                                                         0
110   3662      99   O     PL   109   $                                                                                         0
111   3851      99   O     PL   109   $                                                                                         0
112   4824      99   O     PL   109   $                                                                                         0
113   3927      99   O     PL   109   $                                                                                         0
114   4376      99   O     PL   109   $                                                                                         0
115   4053      99   O     PL   109   $                                                                                         0
116   4844      00   O     PL   109   $                                                                                         0
117   3122      99   O     PL   109   $                                                                                         0
118   1323      99   O     PL   109   $                                                                                         0
119   4244      99   O     PL   109   $                                                                                         0
120   4114      99   O     PL   109   $                                                                                         0
121   3073      99   O     PL   109   $                                                                                         0
122   4751      99   O     PL   109   $                                                                                         0
123   4149      99   O     PL   109   $                                                                                         0
</TABLE>

***   Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

<TABLE>
<CAPTION>

                                     FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
------------------------------------------------------------------------------------------------------------------------------------
            TNX CUST                 SUM OF                                                                                       O
 #  CUST ID YR  TYPE SPECIALTY TER   TNXAMT          NAME              ADDRESS                      CITY          STATE  ZIP     VSL
------------------------------------------------------------------------------------------------------------------------------------
<S> <C>     <C> <C>  <C>       <C> <C>        <C>                      <C>                          <C>             <C> <C>      <C>
124  3749   99  O    PL        109 $                                   [***]                                                       0
125  4353   99  O    PL        109 $                                                                                               0
126  4643   99  O    PL        109 $                                                                                               0
127  3322   99  O    PL        109 $                                                                                               0
128  3612   99  O    PL        109 $                                                                                               0
129  4217   99  O    PL        109 $                                                                                               0
130  4220   99  O    PL        109 $                                                                                               0
131  3536   99  O    PL        109 $                                                                                               0
132  3813   99  O    PL        109 $                                                                                               0
133  3949   99  O    PL        109 $                                                                                               0
134  3074   99  O    PL        109 $                                                                                               0
135  3586   99  O    PL        202 $                                                                                               0
136  3842   99  O    PL        202 $                                                                                               0
137  3605   99  O    PL        202 $                                                                                               0
138  4765   99  O    PL        202                                                                                                 0
139  4717   99  O    PL        202 $                                                                                               0
140  4317   99  O    PL        202 $                                                                                               0
141  4463   99  O    PL        202 $                                                                                               0
142  3886   99  O    PL        202 $                                                                                               0
143  4461   99  O    PL        202 $                                                                                               0
144  4185   99  O    PL        202 $                                                                                               0
145  3562   99  O    PL        202 $                                                                                               0
146  4572   99  O    PL        202 $                                                                                               0
147  4161   99  O    PL        202 $                                                                                               0
148  4335   99  O    PL        202 $                                                                                               0
149  3632   99  O    PL        202 $                                                                                               0
150  4640   99  O    PL        202 $                                                                                               0
151  3669   99  O    PL        202 $                                                                                               0
152  4111   99  O    PL        202 $                                                                                               0
153  3481   99  O    PL        202 $                                                                                               0
154  4470   99  O    PL        202 $                                                                                               0
155  3567   99  O    PL        202 $                                                                                               0
156  3327   99  O    PL        202 $                                                                                               0
157  4088   99  O    PL        202 $                                                                                               0
158  3998   99  O    PL        202 $                                                                                               0
159  3890   99  O    DM        202 $                                                                                               0
160  4044   99  O    PL        202 $                                                                                               0
161  4731   99  O    PL        202 $                                                                                               0
162  3987   99  O    PL        204 $                                                                                               0
163  4448   99  O    PL        204 $                                                                                               0
164  3602   99  O    PL        204 $                                                                                               0

</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

<TABLE>
<CAPTION>
                                     FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
------------------------------------------------------------------------------------------------------------------------------------
            TNX CUST                 SUM OF                                                                                       O
 #  CUST ID YR  TYPE SPECIALTY TER   TNXAMT          NAME              ADDRESS                      CITY          STATE  ZIP     VSL
------------------------------------------------------------------------------------------------------------------------------------
<S> <C>     <C> <C>  <C>       <C> <C>        <C>                      <C>                          <C>             <C> <C>      <C>
165  3516   99  O    PL        204 $                                   [***]                                                       0
166  3845   99  O    PL        204 $                                                                                               0
167  4216   99  O    PL        204 $                                                                                               0
168  4007   99  O    PL        204 $                                                                                               0
169  4592   99  O    PL        204 $                                                                                               0
170  4485   99  O    PL        204 $                                                                                               0
171  3954   99  O    PL        204 $                                                                                               0
172  4224   99  O    PL        204 $                                                                                               0
173  3556   99  O    PL        204 $                                                                                               0
174  4521   99  O    PL        204 $                                                                                               0
175  4638   99  O    PL        204 $                                                                                               0
176  3788   99  O    PL        204 $                                                                                               0
177  3500   99  O    PL        204 $                                                                                               0
178  3804   99  O    PL        204 $                                                                                               0
179  4806   00  O    PL        204                                                                                                 0
180  4519   99  O    PL        204 $                                                                                               0
181  3900   99  O    PL        204 $                                                                                               0
182  3691   99  O    PL        204 $                                                                                               0
183  3779   99  O    PL        204 $                                                                                               0
184  3103   99  O    PL        204 $                                                                                               0
185  4603   00  O    PL        204                                                                                                 0
186  3750   99  O    PL        204 $                                                                                               0
187  3597   99  O    PL        204 $                                                                                               0
188  3953   99  O    PL        204 $                                                                                               0
189  4573   99  O    PL        204 $                                                                                               0
190  4827   00  O    PL        204                                                                                                 0
191  4084   99  O    PL        204 $                                                                                               0
192  3961   99  O    PL        204 $                                                                                               0
193  4398   99  O    PL        206 $                                                                                               0
194  4257   99  O    PL        206 $                                                                                               0
195  3422   99  O    PL        206 $                                                                                               0
196  3211   99  O    PL        206 $                                                                                               0
197  3554   99  O    PL        206 $                                                                                               0
198  9999   00  O    PL        206                                                                                                 0
199  4249   99  O    PL        206 $                                                                                               0
200  4365   99  O    PL        206 $                                                                                               0
201  4396   99  O    PL        206 $                                                                                               0
202  3741   99  O    PL        206 $                                                                                               0

</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                 FINAL OBAGI CUSTOMER LIST 2/9/00  EXHIBIT C
<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                  O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS                CITY      STATE  ZIP   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                         <C>           <C>   <C>   <C>
203    2891   99    O      PL    206  $                                            [***]                                [***]   0
204    4794   00    O      PL    206                                                                                            0
205    4709   99    O      PL    206  $                                                                                         0
206    2725   99    O      PL    206  $                                                                                         0
207    3772   99    O      PL    206  $                                                                                         0
208    2566   99    O      PL    207  $                                                                                         0
209    4649   99    O      PL    207  $                                                                                         0
210    4817   00    O      PL    207                                                                                            0
211    1206   99    O      PL    207  $                                                                                         0
212    2587   99    O      PL    207  $                                                                                         0
213    2466   99    O      PL    207  $                                                                                         0
214    4814   00    O      PL    207                                                                                            0
215    4791   00    O      PL    207                                                                                            0
216    2791   99    O      PL    207  $                                                                                         0
217    4856   00    O      PL    207                                                                                            0
218    4402   99    O      PL    207  $                                                                                         0
219    4790   00    O      PL    208                                                                                            0
220    2995   99    O      PL    208  $                                                                                         0
221    2859   99    O      PL    208  $                                                                                         0
222    2635   99    O      PL    208  $                                                                                         0
223    2720   99    O      PL    208  $                                                                                         0
224    4863         O      PL    209                                                                                            0
225    4577   99    O      PL    209  $                                                                                         0
226    4453   99    O      PL    209  $                                                                                         0
227    2984   99    O      PL    209  $                                                                                         0
228    2539         O      PL    209                                                                                            0
229    4600   99    O      PL    210  $                                                                                         0
230    3661   99    O      PL    210  $                                                                                         0
231    4608   99    O      PL    210  $                                                                                         0
232    4740   99    O      PL    211  $                                                                                         0
233    2796   99    O      PL    211  $                                                                                         0
234    4606   99    O      PL    211  $                                                                                         0
235    3135   99    O      PL    211  $                                                                                         0
236    4833   00    O      PL    211                                                                                            0
237    4561   99    O      PL    211  $                                                                                         0
238    3823   99    O      PL    211  $                                                                                         0
239    2645   99    O      PL    211  $                                                                                         0
240    2787   99    O      PL    211  $                                                                                         0
241    3108   99    O      PL    211  $                                                                                         0
242    3226   99    O      PL    211  $                                                                                         0
243    4516   99    O      PL    211  $                                                                                         0
----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                 FINAL OBAGI CUSTOMER LIST 2/9/00  EXHIBIT C

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                  O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS                CITY      STATE  ZIP   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                         <C>           <C>   <C>   <C>
244    3336   99    O      PL    211  $                                            [***]                                 [***]  0
245    2876   99    O      PL    211  $                                                                                         0
246    1569   99    O      PL    211  $                                                                                         0
247    4520   99    O      PL    211  $                                                                                         0
248    4816   99    O      PL    211                                                                                            0
249    4752   99    O      PL    401                                                                                            0
250    3939   99    O      PL    401  $                                                                                         0
251    2750   99    O      PL    401  $                                                                                         0
252    1269   99    O      PL    401  $                                                                                         0
253    3811   99    O      PL    401  $                                                                                         0
254    3723   99    O      PL    401  $                                                                                         0
255    3421   99    O      PL    401  $                                                                                         0
256    4394   99    O      PL    401  $                                                                                         0
257    3712   99    O      PL    401  $                                                                                         0
258    3522   99    O      PL    401  $                                                                                         0
259    3914   99    O      PL    401  $                                                                                         0
260    3445   99    O      PL    401  $                                                                                         0
261    4635   99    O      PL    401  $                                                                                         0
262    3485   99    O      PL    401  $                                                                                         0
263    4723   99    O      PL    401  $                                                                                         0
264    3824   99    O      PL    401  $                                                                                         0
265    4071   99    O      PL    401  $                                                                                         0
266    1408   99    O      PL    401  $                                                                                         0
267    4337   99    O      PL    401  $                                                                                         0
268    3895   99    O      PL    401  $                                                                                         0
269    4124   99    O      PL    401  $                                                                                         0
270    4788   00    O      PL    401                                                                                            0
271    3593   99    O      PL    401  $                                                                                         0
272    3486   99    O      PL    401  $                                                                                         0
273    3578   99    O      PL    401  $                                                                                         0
274    4484   99    O      PL    401  $                                                                                         0
275    4078   99    O      PL    401  $                                                                                         0
276    2959   99    O      PL    401  $                                                                                         0
277    3801   99    O      PL    401  $                                                                                         0
278    4070   99    O      PL    401  $                                                                                         0
279    1486   99    O      PL    401  $                                                                                         0
280    4848   OO    O      PL    401                                                                                            0
281    3794   99    O      PL    401  $                                                                                         0
282    3598   99    O      PL    401  $                                                                                         0
283    3827   99    O      PL    401  $                                                                                         0
284    3563   99    O      PL    401  $                                                                                         0
----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                       FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
              TNX CUST               SUM OF                                                                                       O
 #   CUST ID  YR  TYPE SPECIALTY TER TNXAMT          NAME                     ADDRESS                CITY         STATE   ZIP  VS L
-----------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C> <C>   <C>    <C>  <C>        <C>                      <C>                          <C>            <C>   <C>    <C>
285    3528   99   O     PL    401  $ [***]                                                                                       O
286    3764   99   O     PL    401  $                                                                                             O
287    3417   99   O     PL    401  $                                                                                             O
288    3589   99   O     PL    401  $                                                                                             O
289    3642   99   O     PL    401  $                                                                                             O
290    3626   99   O     PL    401  $                                                                                             O
291    4750   00   O     PL    404  $                                                                                             O
292    2831   99   O     PL    404  $                                                                                             O
293    1405   99   O     PL    404  $                                                                                             O
294    4099   99   O     PL    404  $                                                                                             O
295    4496   99   O     PL    404  $                                                                                             O
296    2811   99   O     PL    404  $                                                                                             O
297    3883   99   O     PL    404  $                                                                                             O
298    4839   00   O     PL    404  $                                                                                             O
299    4430   99   O     PL    404  $                                                                                             O
300    1283   99   O     PL    404  $                                                                                             O
301    2783   99   O     PL    404  $                                                                                             O
302    2582   99   O     PL    404  $                                                                                             O
303    4616   99   O     PL    404  $                                                                                             O
304    4536   99   O     PL    404  $                                                                                             O
305    4201   99   O     PL    404  $                                                                                             O
306    4832   00   O     PL    404  $                                                                                             O
307    3724   99   O     PL    404  $                                                                                             O
308    2801   99   O     PL    404  $                                                                                             O
309    2601   99   O     PL    404  $                                                                                             O
310    2589   99   O     PL    404  $                                                                                             O
311    2568   99   O     PL    404  $                                                                                             O
312    3809   99   O     PL    404  $                                                                                             O
313    2559   99   O     PL    404  $                                                                                             O
314    3872   99   O     PL    404  $                                                                                             O
315    4745   00   O     PL    405  $                                                                                             O
316    4444   99   O     PL    405  $                                                                                             O
317    3704   99   O     PL    405  $                                                                                             O
318    4769   00   O     PL    405  $                                                                                             O
319    4730   99   O     PL    405  $                                                                                             O
320    4502   99   O     PL    405  $                                                                                             O
321    3345   99   O     PL    405  $                                                                                             O
322    4834   00   O     PL    405  $                                                                                             O
323    4807   00   O     PL    405  $                                                                                             O
324    4388   99   O     PL    405  $                                                                                             O
325    4541   99   O     PL    405  $                                                                                             O

</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                       FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
              TNX CUST               SUM OF                                                                                       O
 #   CUST ID  YR  TYPE SPECIALTY TER TNXAMT          NAME                     ADDRESS                CITY         STATE   ZIP  VS L
-----------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C> <C>   <C>    <C>  <C>        <C>                      <C>                          <C>            <C>   <C>    <C>
326    4550   99   O     PL    405  $ [***]                                                                                       O
327    4818   00   O     PL    405  $                                                                                             O
328    3879   99   O     PL    405  $                                                                                             O
329    3356   99   O     PL    405  $                                                                                             O
330    3963   99   O     PL    405  $                                                                                             O
331    4406   99   O     PL    406  $                                                                                             O
332    3825   99   O     PL    406  $                                                                                             O
333    3313   99   O     PL    406  $                                                                                             O
334    4465   99   O     PL    406  $                                                                                             O
335    4703   99   O     PL    406  $                                                                                             O
336    4087   99   O     PL    406  $                                                                                             O
337    3985   99   O     PL    406  $                                                                                             O
338    3812   99   O     PL    406  $                                                                                             O
339    4341   99   O     PL    406  $                                                                                             O
340    4757   00   O     PL    406  $                                                                                             O
341    4098   99   O     PL    406  $                                                                                             O
342    4611   99   O     PL    406  $                                                                                             O
343    4338   99   O     PL    406  $                                                                                             O
344    4307   99   O     PL    406  $                                                                                             O
345    4178   99   O     PL    406  $                                                                                             O
346    4348   99   O     PL    406  $                                                                                             O
347    3694   99   O     PL    406  $                                                                                             O
348    3395   99   O     PL    406  $                                                                                             O
349    4134   99   O     PL    406  $                                                                                             O
350    3291   99   O     PL    406  $                                                                                             O
351    4800   00   O     PL    406  $                                                                                             O
352    3991   99   O     PL    406  $                                                                                             O
353    4231   99   O     PL    406  $                                                                                             O
354    3565   99   O     PL    406  $                                                                                             O
355    4443   99   O     PL    406  $                                                                                             O
356    3962   99   O     PL    406  $                                                                                             O
357    3679   99   O     PL    407  $                                                                                             O
358    3904   99   O     PL    407  $                                                                                             O
359    3096   99   O     PL    407  $                                                                                             O
360    4771   00   O     PL    407  $                                                                                             O
361    3810   99   O     PL    407  $                                                                                             O
362    4852   00   O     PL    407  $                                                                                             O
363    3203   99   O     PL    407  $                                                                                             O
364    4513   99   O     PL    407  $                                                                                             O
365    2436   99   O     PL    407  $                                                                                             O
366    4199   99   O     PL    407  $                                                                                             O
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                   FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C

<TABLE>
<CAPTION>

 #  CUST  TAX CUST             SUM OF                                                                                   O
     ID    YR TYPE OECIA TER  TAX AMT      NAME                     ADDRESS                  CITY       STATE    ZIP   VS L
============================================================================================================================
<C>  <C>  <C> <C>  <C> <C> <C>        <C>                      <C>                          <C>           <C>    <C>    <C>
367  2953  99  0    PL  407 $ [***]                                                                                      0
368  2449  99  0    PL  407 $                                                                                            0
369  4210  99  0    PL  407 $                                                                                            0
370  4015  99  0    PL  407 $                                                                                            0
371  4584  99  0    PL  408 $                                                                                            0
372  1487  99  0    PL  408 $                                                                                            0
373  4088  99  0    PL  408 $                                                                                            0
374  3719  99  0    PL  408 $                                                                                            0
375  3680  99  0    PL  408 $                                                                                            0
376  3439  99  0    PL  408 $                                                                                            0
377  4566  99  0    PL  408 $                                                                                            0
378  4813  00  0    PL  408 $                                                                                            0
379  4382  99  0    PL  408 $                                                                                            0
380  3139  99  0    PL  408 $                                                                                            0
381  3574  99  0    PL  408 $                                                                                            0
382  3454  99  0    PL  408 $                                                                                            0
383  4085  99  0    PL  408 $                                                                                            0
384  4340  99  0    PL  408 $                                                                                            0
385  4447  99  0    PL  408 $                                                                                            0
386  1454  99  0    PL  408 $                                                                                            0
387  4136  99  0    PL  408 $                                                                                            0
388  3778  99  0    PL  408 $                                                                                            0
389  4826  00  0    PL  408 $                                                                                            0
390  4747  99  0    PL  408 $                                                                                            0
391  4706  99  0    PL  408 $                                                                                            0
392  3065  99  0    PL  408 $                                                                                            0
393  4822  00  0    PL  408 $                                                                                            0
394  3684  99  0    PL  408 $                                                                                            0
395  4278  99  0    PL  408 $                                                                                            0
396  4128  99  0    PL  408 $                                                                                            0
397  3529  99  0    PL  408 $                                                                                            0
398  3725  99  0    PL  408 $                                                                                            0
399  4295  99  0    PL  408 $                                                                                            0
400  4409  99  0    PL  408 $                                                                                            0
401  3618  99  0    PL  408 $                                                                                            0
402  3983  99  0    PL  408 $                                                                                            0
403  4540  99  0    PL  408 $                                                                                            0
404  1501  99  0    PL  409 $                                                                                            0
405  3926  99  0    PL  409 $                                                                                            0
406  4411  99  0    PL  409 $                                                                                            0
407  4180  99  0    PL  409 $                                                                                            0

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

408  3695  99  0    PL  409 $ [***]                                                                                      0
409  3408  99  0    PL  409 $                                                                                            0
410  3948  99  0    PL  409 $                                                                                            0
411  1618  99  0    PL  899 $                                                                                            0
412  2569  99  0    PL  899 $                                                                                            0
413  2858  99  0    PL  899 $                                                                                            0
414  2565  99  0    PL  899 $                                                                                            0
415  1742  99  0    PL  899 $                                                                                            0
416  2967  99  0    PL  899 $                                                                                            0
417  4410  99  0    PL  899 $                                                                                            0
418  3700  99  0    PL  899 $                                                                                            0
419  1677  99  0    PL  899 $                                                                                            0
420  3201  99  0    PL  899 $                                                                                            0
421  4727  99  0    PL  899 $                                                                                            0
422  1635  99  0    PL  899 $                                                                                            0
----------------------------------------------------------------------------------------------------------------------------
                            $
----------------------------------------------------------------------------------------------------------------------------
       TOTAL ACCOUNTS FOR OBAGI =
============================================================================================================================
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                     FINAL LIFECELL CUSTOMER LIST 2/9/2000

                                  EXHIBIT D

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                    O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS            CITY      STATE  ZIP   #   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                     <C>           <C>   <C>  <C>   <C>
 1   3240     99   O     PL     101   $ [***]          [***]                                                               9    L
 2   3344     99   O     PL     101   $                                                                                    8    L
 3   1332     99   O     PL     101   $                                                                                    12   L
 4   4176     99   O     PL     101   $                                                                                    5    L
 5   3025     99   O     PL     101   $                                                                                    7    L
 6   3834     99   O     PL     101   $                                                                                    2    L
 7   4169     99   O     PL     101   $                                                                                    1    L
 8   3551     99   O     PL     101   $                                                                                    7    L
 9   4221     99   O     PL     101   $                                                                                    2    L
10   4369     99   O     PL     101   $                                                                                    1    L
11   3189     99   O     PL     101   $                                                                                    2    L
12   3726     99   O     PL     101   $                                                                                    3    L
13   4712     99   O     PL     101   $                                                                                    2    L
14   4147     99   O     PL     101   $                                                                                    3    L
15   1565     99   O     PL     102   $                                                                                    3    L
16   3131     99   O     PL     102   $                                                                                    8    L
17   3090     99   O     PL     102   $                                                                                    4    L
18   3016     99   O     PL     102   $                                                                                    7    L
19   3204     99   O     PL     102   $                                                                                    7    L
20   3492     99   O     PL     102   $                                                                                    3    L
21   3138     99   O     PL     102   $                                                                                    3    L
22   4184     99   O     PL     102   $                                                                                    1    L
23   4287     99   O     PL     102   $                                                                                    2    L
24   3057     99   O     PL     102   $                                                                                    2    L
25   3627     99   O     PL     102   $                                                                                    2    L
26   1352     99   O     PL     102   $                                                                                    1    L
27   3754     99   O     PL     102   $                                                                                    1    L
28   4153     99   O     PL     102   $                                                                                    1    L
29   4507     99   O     PL     102   $                                                                                    1    L
30   4515     99   O     PL     102   $                                                                                    1    L
31   3051     99   O     DM     103   $                                                                                    6    L
32   4066     99   O     PL     103   $                                                                                    5    L
33   3202     99   O     PL     103   $                                                                                    8    L
34   4630     99   O     PL     103   $                                                                                    1    L
35   4633     99   O     PL     103   $                                                                                    1    L
36   2518     99   O     PL     103   $                                                                                    9    L
37   3230     99   O     PL     103   $                                                                                    3    L
38   4407     99   O     PL     103   $                                                                                    2    L
39   3401     99   O     PL     103   $                                                                                    4    L
40   3716     99   O     PL     103   $                                                                                    3    L
41   2530     99   O     PL     103   $                                                                                    4    L
42   3857     99   O     PL     103   $                                                                                    3    L
43   3631     99   O     PL     103   $                                                                                    1    L
44   4040     99   O     PL     103   $                                                                                    1    L
45   3212     99   O     PL     103   $                                                                                    1    L
46   4343     99   O     PL     103   $                                                                                    1    L
47   3199     99   O     PL     103   $                                                                                    3    L
48   3427     99   O     PL     103   $                                                                                    1    L
49   4629     00   O     PL     103   $                                                                                         L
50   2972     99   O     PL     104   $                                                                                    10   L
51   1515     99   O     PL     104   $                                                                                    12   L
52   4092     99   O     PL     104   $                                                                                    4    L
53   3403     99   O     PL     104   $                                                                                    2    L
54   3535     99   O     PL     104   $                                                                                    1    L
55   4427     99   O     PL     104   $                                                                                    3    L
56   4122     99   O     PL     104   $                                                                                    1    L
57   4495     99   O     PL     104   $                                                                                    2    L
58   4518     99   O     PL     104   $                                                                                    1    L
59   4732     99   O     PL     104   $                                                                                    1    L
60   4275     99   O     PL     104   $                                                                                    5    L
61   4125     99   O     PL     104   $                                                                                    2    L
62   3003     99   O     PL     104   $                                                                                    3    L
63   2487     99   O     PL     104   $                                                                                    1    L
64   3630     99   O     PL     104   $                                                                                    1    L
65   1375     99   O     PL     105   $                                                                                    7    L
66   3066     99   O     PL     105   $                                                                                    12   L
67   2919     99   O     PL     105   $                                                                                    8    L
68   3180     99   O     PL     105   $                                                                                    7    L
69   1393     99   O     PL     105   $                                                                                    4    L
70   3020     99   O     PL     105   $                                                                                    4    L
71   3120     99   O     PL     105   $                                                                                    6    L
72   2974     99   O     PL     105   $                                                                                    8    L
73   3352     99   O     PL     105   $                                                                                    8    L
74   3088     99   O     PL     105   $                                                                                    8    L
75   3497     99   O     PL     105   $                                                                                    6    L
76   2907     99   O     PL     105   $                                                                                    7    L
77   2935     99   O     PL     105   $                                                                                    2    L
78   4288     99   O     PL     105   $                                                                                    2    L
79   3653     99   O     PL     105   $                                                                                    4    L
80   3936     99   O     PL     105   $                                                                                    3    L
81   3229     99   O     PL     105   $                                                                                    3    L
82   2918     99   O     PL     105   $                                                                                    7    L
83   3102     99   O     PL     105   $                                                                                    3    L
84   4401     99   O     PL     105   $                                                                                    2    L

</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                 FINAL LIFECELL CUSTOMER LIST 2/9/2000  EXHIBIT D

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                    O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS            CITY      STATE  ZIP   #   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                     <C>           <C>   <C>  <C>   <C>
85   4273      99   O    PL     105   $ [***]                                                                              3     L
86   3970      99   O    PL     105   $                                                                                    1     L
87   4650      00   O    PL     105                                                                                              L
88   9999      00   O    PL     105                                                                                              L
89   3410      00   O    PL     106                                                                                              L
90   4874      00   O    PL     106                                                                                              L
91   4875      00   O    PL     106                                                                                              L
92   4876      00   O    PL     106                                                                                              L
93   4877      00   O    PL     106                                                                                              L
94   4878      00   O    PL     106                                                                                              L
95   4879      00   O    PL     106                                                                                              L
96   4880      00   O    PL     106                                                                                              L
97   4881      00   O    PL     106                                                                                              L
98   4883      00   O    PL     106                                                                                              L
99   4884      00   O    PL     106                                                                                              L
100  4885      00   O    PL     106                                                                                              L
101  4886      00   O    PL     106                                                                                              L
102  4888      00   O    PL     106                                                                                              L
103  3447      99   O    PL     107   $                                                                                    6     L
104  3663      99   O    PL     107   $                                                                                    3     L
105  3155      99   O    PL     107   $                                                                                    3     L
106  3951      99   O    PL     107   $                                                                                    7     L
107  4497      99   O    PL     107   $                                                                                    3     L
108  3566      99   O    PL     107   $                                                                                    6     L
109  4274      99   O    PL     107   $                                                                                    4     L
110  3892      99   O    PL     107   $                                                                                    6     L
111  3127      99   O    PL     107   $                                                                                    3     L
112  4300      99   O    PL     107   $                                                                                    3     L
113  4602      99   O    PL     107   $                                                                                    2     L
114  4258      99   O    PL     107   $                                                                                    1     L
115  2606      99   O    PL     107   $                                                                                    3     L
116  2604      99   O    PL     107   $                                                                                    2     L
117  4437      99   O    PL     107   $                                                                                    1     L
118  3740      99   O    PL     107   $                                                                                    2     L
119  3906      99   O    PL     107   $                                                                                    1     L
120  4619      99   O    PL     107   $                                                                                    1     L
121  2611      99   O    PL     107   $                                                                                    1     L
122  4266      99   O    PL     107   $                                                                                    2     L
123  3038      99   O    DM     108   $                                                                                    10    L
124  3330      99   O    PL     108   $                                                                                    18    L
125  2609      99   O    PL     108   $                                                                                    4     L
126  2602      99   O    PL     108   $                                                                                    6     L
----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                    O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS            CITY      STATE  ZIP   #   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                     <C>           <C>   <C>  <C>   <C>
127   3727     99   O     PL     108  $ [***]                                                                              9     L
128   4001     99   O     PL     108  $                                                                                    6     L
129   3079     99   O     PL     108  $                                                                                    9     L
130   2893     99   O     PL     108  $                                                                                    7     L
131   3130     99   O     PL     108  $                                                                                    12    L
132   2920     99   O     PL     108  $                                                                                    21    L
133   2979     99   O     DM     108  $                                                                                    4     L
134   3217     99   O     DM     108  $                                                                                    3     L
135   2982     99   O     PL     108  $                                                                                    6     L
136   3106     99   O     PL     108  $                                                                                    5     L
137   1374     99   O     PL     108  $                                                                                    1     L
138   4628     00   O     PL     106  $                                                                                    1     L
139   3606     99   O     PL     108  $                                                                                    13    L
140   2901     99   O     PL     108  $                                                                                    4     L
141   2622     99   O     PL     108  $                                                                                    4     L
142   3366     99   O     PL     108  $                                                                                    10    L
143   3560     99   O     PL     108  $                                                                                    5     L
144   3125     99   O     PL     108  $                                                                                    7     L
145   4554     99   O     PL     108  $                                                                                    2     L
146   3235     99   O     PL     108  $                                                                                    2     L
147   3484     99   O     PL     109  $                                                                                    13    L
148   3085     99   O     PL     109  $                                                                                    13    L
149   3333     99   O     PL     109  $                                                                                    7     L
150   3634     99   O     PL     109  $                                                                                    6     L
151   3646     99   O     PL     109  $                                                                                    3     L
152   3112     99   O     PL     109  $                                                                                    1     L
153   3833     99   O     PL     109  $                                                                                    4     L
154   4016     99   O     PL     109  $                                                                                    2     L
155   3935     99   O     PL     109  $                                                                                    3     L
156   3238     99   O     PL     109  $                                                                                    4     L
157   3210     99   O     PL     109  $                                                                                    4     L
158   3039     99   O     PL     109  $                                                                                    5     L
159   3222     99   O     PL     109  $                                                                                    2     L
160   3188     99   O     PL     109  $                                                                                    4     L
161   4247     99   O     PL     109  $                                                                                    1     L
162   2053     99   O     PL     109  $                                                                                    2     L
163   3603     99   O     PL     202  $                                                                                    3     L
164   3328     99   O     PL     202  $                                                                                    6     L
165   3380     99   O     PL     202  $                                                                                    5     L
166   3511     99   O     PL     202  $                                                                                    4     L
167   3404     99   O     PL     202  $                                                                                    9     L
168   3796     99   O     PL     202  $                                                                                    2     L
-----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                     FINAL LIFECELL CUSTOMER LIST 2/9/2000     EXHIBIT D
<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                    O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS            CITY      STATE  ZIP   #   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                     <C>           <C>   <C>  <C>   <C>
169    4063   99     O    PL    202   $ [***]                                   [***]                                      2     L
170    4200   99     O    PL    202   $                                                                                    2     L
171    4357   99     O    PL    202   $                                                                                    2     L
172    3696   99     O    PL    202   $                                                                                    4     L
173    3613   99     O    PL    202   $                                                                                    4     L
174    3388   99     O    PL    202   $                                                                                    2     L
175    3981   99     O    PL    202   $                                                                                    1     L
176    4364   99     O    PL    202   $                                                                                    1     L
177    4223   99     O    PL    202   $                                                                                    2     L
178    4460   99     O    PL    202   $                                                                                    1     L
179    3436   99     O    PL    204   $                                                                                   15     L
180    3881   99     O    PL    204   $                                                                                    9     L
181    3350   99     O    PL    204   $                                                                                   12     L
182    3514   99     O    PL    204   $                                                                                    6     L
183    3671   99     O    PL    204   $                                                                                    6     L
184    3570   99     O    PL    204   $                                                                                   10     L
185    3739   99     O    PL    204   $                                                                                    6     L
186    3707   99     O    PL    204   $                                                                                    4     L
187    3874   99     O    PL    204   $                                                                                    4     L
188    4454   99     O    PL    204   $                                                                                    3     L
189    3807   99     O    PL    204   $                                                                                    2     L
190    3469   99     O    PL    204   $                                                                                    4     L
191    3850   99     O    PL    204   $                                                                                    1     L
192    4089   99     O    PL    204   $                                                                                    2     L
193    4091   99     O    PL    204   $                                                                                    2     L
194    3326   99     O    PL    204   $                                                                                    3     L
195    3406   99     O    PL    204   $                                                                                    3     L
196    3910   99     O    PL    204   $                                                                                    4     L
197    3458   99     O    PL    204   $                                                                                    3     L
198    3331   99     O    PL    204   $                                                                                    2     L
199    3451   99     O    PL    206   $                                                                                   11     L
200    3579   99     O    PL    206   $                                                                                   10     L
201    3548   99     O    PL    206   $                                                                                    4     L
202    3715   99     O    PL    206   $                                                                                    6     L
203    4116   99     O    PL    206   $                                                                                    5     L
204    3068   99     O    PL    206   $                                                                                    5     L
205    3493   99     O    PL    206   $                                                                                    5     L
206    4377   99     O    PL    206   $                                                                                    2     L
207    4504   99     O    PL    206   $                                                                                    2     L
208    3190   99     O    PL    206   $                                                                                    4     L
209    3273   99     O    PL    206   $                                                                                    4     L
210    1654   99     O    PL    208   $                                                                                    4     L
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                     FINAL LIFECELL CUSTOMER LIST 2/9/2000     EXHIBIT D

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                    O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS            CITY      STATE  ZIP   #   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                     <C>           <C>   <C>  <C>   <C>
211    3341   99     O    PL    206   $ [***]                                    [***]                                     2     L
212    3547   99     O    PL    206   $                                                                                    1     L
213    3645   99     O    PL    206   $                                                                                    2     L
214    4825   00     O    PL    206                                                                                              L
215    9999   00     O    PL    206                                                                                              L
216    1543   99     O    PL    207   $                                                                                   18     L
217    2913   99     O    PL    207   $                                                                                   28     L
218    3158   99     O    PL    207   $                                                                                    7     L
219    1604   99     O    PL    207   $                                                                                    7     L
220    2467   99     O    PL    207   $                                                                                   16     L
221    2870   99     O    PL    207   $                                                                                    9     L
222    1462   99     O    PL    207   $                                                                                    5     L
223    1571   99     O    PL    207   $                                                                                    4     L
224    3096   99     O    PL    207   $                                                                                    6     L
225    2922   99     O    PL    207   $                                                                                    3     L
226    2753   99     O    PL    207   $                                                                                    2     L
227    2411   99     O    PL    207   $                                                                                    4     L
228    2985   99     O    PL    207   $                                                                                    3     L
229    1589   99     O    PL    207   $                                                                                    3     L
230    3205   99     O    PL    207   $                                                                                    2     L
231    1337   99     O    PL    207   $                                                                                   11     L
232    2590   99     O    PL    207   $                                                                                    2     L
233    3544   99     O    PL    207   $                                                                                    3     L
234    3545   99     O    PL    207   $                                                                                    1     L
235    1557   99     O    PL    207   $                                                                                    1     L
236    2456   99     O    PL    208   $                                                                                    9     L
237    2470   99     O    PL    208   $                                                                                   14     L
238    2324   99     O    PL    208   $                                                                                    5     L
239    1743   99     O    PL    208   $                                                                                    7     L
240    4627   99     O    PL    208   $                                                                                    1     L
241    4634   99     O    PL    208   $                                                                                    1     L
242    2423   99     O    PL    208   $                                                                                    2     L
243    2763   99     O    PL    208   $                                                                                    5     L
244    1636   99     O    PL    208   $                                                                                    5     L
245    3795   99     O    PL    208   $                                                                                    1     L
246    2401   99     O    PL    208   $                                                                                    2     L
247    2885   99     O    PL    208   $                                                                                    5     L
248    4162   99     O    PL    208   $                                                                                    1     L
249    3937   99     O    PL    208   $                                                                                    2     L
250    2618   99     O    PL    208   $                                                                                    1     L
251    2595   99     O    PL    208   $                                                                                    1     L
252    3588   99     O    PL    208   $                                                                                    1     L
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.
<PAGE>

<TABLE>
<CAPTION>

                                        FINAL LIFECELL CUSTOMER LIST 2/9/2000   EXHIBIT D
-----------------------------------------------------------------------------------------------------------------------------------
    CUST  TNX CUST SPECI-      SUM OF                                                                                          O
 #   ID   YR  TYPE ALTY  TER  TNXAMT           NAME                        ADDRESS                CITY        STATE  ZIP     # VS L
-----------------------------------------------------------------------------------------------------------------------------------
<S> <C>   <C> <C>  <C>  <C> <C>        <C>                          <C>                         <C>           <C>  <C>       <C><C>
253  4860      O   PL   208    [***]                                                                                             L
254  4861      O   PL   208                                                                                                      L
255  4862      O   PL   208                                                                                                      L
256  4869      O   PL   208                                                                                                      L
257  2735  99  O   PL   209 $                                                                                                 14 L
258  1595  99  O   PL   209 $                                                                                                 31 L
259  2825  99  O   PL   209 $                                                                                                 11 L
260  1630  99  O   PL   209 $                                                                                                 15 L
261  1457  99  O   PL   209 $                                                                                                  5 L
262  2858  99  O   PL   209 $                                                                                                  6 L
263  2553  99  O   PL   209 $                                                                                                  8 L
264  2589  99  O   PL   209 $                                                                                                  5 L
265  2453  99  O   PL   209 $                                                                                                  4 L
266  3513  99  O   PL   209 $                                                                                                  9 L
267  2893  99  O   PL   209 $                                                                                                  5 L
268  2550  99  O   PL   209 $                                                                                                  4 L
269  3054  99  O   PL   209 $                                                                                                  3 L
270  1148  99  O   PL   209 $                                                                                                  3 L
271  2440  99  O   PL   209 $                                                                                                  1 L
272  4434  99  O   PL   209 $                                                                                                  2 L
273  4009  99  O   PL   209 $                                                                                                  2 L
274  4547  99  O   PL   209 $                                                                                                  1 L
275  4746      O   PL   209                                                                                                      L
276  2572  99  O   PL   210 $                                                                                                 14 L
277  2473  99  O   PL   210 $                                                                                                  9 L
278  2649  99  O   PL   210 $                                                                                                  5 L
279  3743  99  O   PL   210 $                                                                                                  1 L
280  1504  99  O   PL   210 $                                                                                                  5 L
281  4404  99  O   PL   210 $                                                                                                  3 L
282  4374  99  O   PL   210 $                                                                                                  1 L
283  4483  99  O   PL   210 $                                                                                                  1 L
284  4304  99  O   PL   210 $                                                                                                  1 L
285  4866      O   PL   210                                                                                                      L
286  4867      O   PL   210                                                                                                      L
287  4868      O   PL   210                                                                                                      L
288  1534  99  O   PL   211 $                                                                                                 17 L
289  2746  99  O   PL   211 $                                                                                                  8 L
290  2764  99  O   PL   211 $                                                                                                 11 L
291  3167  99  O   PL   211 $                                                                                                  5 L
292  2947  99  O   PL   211 $                                                                                                  4 L
293  4218  99  O   PL   211 $                                                                                                  1 L
294  2917  99  O   PL   211 $

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

<CAPTION>

                                        FINAL LIFECELL CUSTOMER LIST 2/9/2000   EXHIBIT D
-----------------------------------------------------------------------------------------------------------------------------------
    CUST  TNX CUST SPECI-      SUM OF                                                                                          O
 #   ID   YR  TYPE ALTY  TER  TNXAMT           NAME                        ADDRESS                CITY        STATE  ZIP     # VS L
-----------------------------------------------------------------------------------------------------------------------------------
<S> <C>   <C> <C>  <C>  <C> <C>        <C>                          <C>                         <C>           <C>  <C>       <C><C>
295  2639  99  O   PL   211 $ [***]                                                                                            3 L
296  2631  99  O   PL   211 $                                                                                                  2 L
297  2892  99  O   PL   211 $                                                                                                  2 L
298  4322  99  O   PL   211 $                                                                                                  1 L
299  2879  99  O   PL   211 $                                                                                                  1 L
300  2903  99  O   PL   211 $                                                                                                  2 L
301  2899  99  O   PL   211 $                                                                                                  2 L
302  3621  99  O   PL   401 $                                                                                                 13 L
303  3349  99  O   PL   401 $                                                                                                 23 L
304  3348  99  O   PL   401 $                                                                                                  5 L
305  3546  99  O   PL   401 $                                                                                                  5 L
306  3457  99  O   PL   401 $                                                                                                 16 L
307  3495  99  O   PL   401 $                                                                                                 16 L
308  1396  99  O   PL   401 $                                                                                                  2 L
309  3324  99  O   PL   401 $                                                                                                 12 L
310  1460  99  O   PL   401 $                                                                                                 14 L
311  3353  99  O   PL   401 $                                                                                                  5 L
312  3777  99  O   PL   401 $                                                                                                  4 L
313  4129  99  O   PL   401 $                                                                                                  5 L
314  1614  99  O   PL   401 $                                                                                                  7 L
315  4135  99  O   PL   401 $                                                                                                  2 L
316  3822  99  O   PL   401 $                                                                                                  3 L
317  3944  99  O   PL   401 $                                                                                                  3 L
318  2734  99  O   PL   401 $                                                                                                  4 L
319  3688  99  O   PL   401 $                                                                                                  2 L
320  4356  99  O   PL   401 $                                                                                                  2 L
321  2540  99  O   PL   404 $                                                                                                 17 L
322  2653  99  O   PL   404 $                                                                                                 13 L
323  1482  99  O   PL   404 $                                                                                                  8 L
324  3880  99  O   PL   404 $                                                                                                  5 L
325  2797  99  O   PL   404 $                                                                                                  7 L
326  2762  99  O   PL   404 $                                                                                                  4 L
327  4029  99  O   PL   404 $                                                                                                  2 L
328  2576  99  O   PL   404 $                                                                                                  6 L
329  2789  99  O   PL   404 $                                                                                                  3 L
330  3162  99  O   PL   404 $                                                                                                  3 L
331  2632  99  O   PL   404 $                                                                                                  3 L
332  2956  99  O   PL   404 $                                                                                                  2 L
333  2963  99  O   PL   404 $                                                                                                  3 L
334  3693  99  O   PL   404 $                                                                                                  3 L
335  3873  99  O   PL   404 $                                                                                                  5 L
336  2197  99  O   PL   405 $                                                                                                  7 L
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.
<PAGE>

              Final LifeCell Customer List 2/9/2000     EXHIBIT D

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                    O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS            CITY      STATE  ZIP   #   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                     <C>           <C>   <C>  <C>   <C>
337  3475     99    O    PL     405     [***]                                     [***]                                    9    L
338  3768     99    O    PL     405                                                                                        4    L
339  3523     99    O    PL     405                                                                                        6    L
340  3533     99    O    PL     405                                                                                        4    L
341  3520     99    O    PL     405                                                                                        4    L
342  3697     99    O    PL     405                                                                                        4    L
343  3315     99    O    PL     405                                                                                        3    L
344  3424     99    O    PL     405                                                                                        3    L
345  3701     99    O    PL     405                                                                                        3    L
346  3420     99    O    PL     405                                                                                        3    L
347  4236     99    O    PL     405                                                                                        2    L
348  3718     99    O    PL     405                                                                                        1    L
349  3912     99    O    PL     405                                                                                        2    L
350  3913     99    O    PL     405                                                                                        1    L
351  4378     99    O    PL     405                                                                                        2    L
352  4735     99    O    PL     405                                                                                        1    L
353  4753     99    O    PL     405                                                                                        2    L
354  3274     99    O    PL     406                                                                                        9    L
355  3321     99    O    PL     406                                                                                       11    L
356  3246     99    O    PL     406                                                                                        5    L
357  3465     99    O    PL     406                                                                                        7    L
358  3293     99    O    PL     406                                                                                        6    L
359  1288     99    O    PL     406                                                                                       10    L
360  3294     99    O    PL     406                                                                                        8    L
361  4167     99    O    PL     406                                                                                        2    L
362  3281     99    O    PL     406                                                                                        5    L
363  4445     99    O    PL     406                                                                                        1    L
364  3266     99    O    PL     406                                                                                        2    L
365  4182     99    O    PL     406                                                                                        3    L
366  3278     99    O    PL     406                                                                                        3    L
367  3368     99    O    PL     406                                                                                        5    L
368  3300     99    O    PL     406                                                                                        1    L
369  4035     99    O    PL     406                                                                                        1    L
370  3309     99    O    PL     406                                                                                        3    L
371  4522     99    O    PL     406                                                                                        3    L
372  3390     99    O    PL     406                                                                                        2    L
373  3253     99    O    PL     406                                                                                        2    L
374  3310     99    O    PL     406                                                                                        3    L
375  3683     99    O    PL     406                                                                                        1    L
376  2992     99    O    PL     407                                                                                       14    L
377  3007     99    O    PL     407                                                                                        5    L
378  2998     99    O    PL     407                                                                                       10    L
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                    O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS            CITY      STATE  ZIP   #   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                     <C>           <C>   <C>  <C>   <C>
379  3814      99   O     PL    407      [***]                                    [***]                                     9    L
380  3119      99   O     PL    407                                                                                        10    L
381  3393      99   O     PL    407                                                                                         6    L
382  3244      99   O     PL    407                                                                                         3    L
383  2404      99   O     PL    407                                                                                         4    L
384  4277      99   O     PL    407                                                                                         3    L
385  3785      99   O     PL    407                                                                                         5    L
386  2981      99   O     PL    407                                                                                         2    L
387  2410      99   O     PL    407                                                                                         2    L
388  2427      99   O     PL    407                                                                                         1    L
389  4171      99   O     PL    407                                                                                         1    L
390  4553      99   O     PL    407                                                                                         1    L
391  3312      99   O     PL    408                                                                                        70    L
392  3393      99   O     PL    408                                                                                        17    L
393  3369      99   O     PL    408                                                                                        15    L
394  3549      99   O     PL    408                                                                                         4    L
395  3453      99   O     PL    408                                                                                        21    L
396  3243      99   O     PL    408                                                                                         7    L
397  4093      99   O     PL    408                                                                                         8    L
398  3705      99   O     PL    408                                                                                        14    L
399  3601      99   O     PL    408                                                                                         5    L
400  4193      99   O     PL    408                                                                                         2    L
401  3339      99   O     PL    408                                                                                         7    L
402  3437      99   O     PL    408                                                                                         4    L
403  3430      99   O     PL    408                                                                                         4    L
404  4138      99   O     PL    408                                                                                         5    L
405  4252      99   O     PL    408                                                                                         2    L
406  3323      99   O     PL    408                                                                                         6    L
407  3569      99   O     PL    408                                                                                         6    L
408  4097      99   O     PL    408                                                                                         2    L
409  4479      99   O     PL    408                                                                                         1    L
410  4657      99   O     PL    408                                                                                         1    L
411  4632      00   O     PL    408                                                                                              L
412  4651      99   O     PL    408                                                                                              L
413  9999      00   O     PL    408                                                                                              L
414  9999      00   O     PL    408                                                                                              L
415  9999      00   O     PL    408                                                                                              L
416  3673      99   O     PL    409                                                                                         6    L
417  3608      99   O     PL    409                                                                                         5    L
418  3620      99   O     PL    409                                                                                         6    L
419  3745      99   O     PL    409                                                                                         9    L
420  3917      99   O     PL    409                                                                                         7    L
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
              TAX  CUST                SUM OF                                                                                    O
  #  CUST ID  YR   TYPE  PECIA  TER    TAX AMT          NAME                     ADDRESS            CITY      STATE  ZIP   #   VS L
------------------------------------------------------------------------------------------------------------------------------------
<S>  <C>      <C>  <C>   <C>    <C>  <C>        <C>                      <C>                     <C>           <C>   <C>  <C>   <C>
421  3558     99    O    PL     409      [***]                                    [***]                                    2    L
422  3826     99    O    PL     409                                                                                        3    L
423  3555     99    O    PL     409                                                                                        4    L
424  3373     99    O    PL     409                                                                                        6    L
425  3503     99    O    PL     409                                                                                        7    L
426  3414     99    O    PL     409                                                                                        4    L
427  3584     99    O    PL     409                                                                                        3    L
428  3786     99    O    PL     409                                                                                        2    L
429  3891     99    O    PL     409                                                                                        1    L
430  3933     99    O    PL     409                                                                                        1    L
431  4067     99    O    PL     409                                                                                        1    L
432  4544     99    O    PL     409                                                                                        2    L
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

        Total count for LifeCall List =

[***] Material has been omitted pursuant to a request for confidential
      treatment and such material has been filed separately with the
      Securities and Exchange Commission.

<PAGE>

                                    EXHIBIT E

   PRODUCT STORAGE, HANDLING AND TRANSPORTATION SPECIFICATIONS AND PROCEDURES

The following policies and procedures are based on the Standards of the
American Association of Tissue Banks (1996) and specifically address the
issue of "Tissue Distribution Intermediates" (Section M). Technical
assistance is available from LifeCell to facilitate the incorporation of
these procedures.

Appropriate documentation is critical. Particular attention should be paid to
the following areas:

         Documentation of receipt of tissue
            Lot/graft numbers
            Expiration date
            Received by
            Date of receipt
            Condition of packaging

         Documentation of storage conditions
            Temperature monitoring

         Documentation of distribution
            Date of order
            Consignee name and address
            Identification of person placing the order
            Type and quantity of tissue ordered
            Information regarding tissue shipped
                Identification number(s) of tissue(s)
                Expiration date of tissue
                Date of shipment
                Mode of transportation
                Name of Individual filling order

         Documentation of final package inspection prior to distribution

ADDITIONAL REQUIREMENTS:

STORAGE EQUIPMENT
All storage equipment (i.e., refrigerator(s)) must be regularly maintained (i.e.
preventative maintenance program)), calibrated, and monitored.

Monitoring of refrigerators may consist of the installation of a continuous
temperature recording device or a routine (once each working day) and DOCUMENTED
check of temperature utilizing a refrigerator thermometer. Acceptable
temperature range for the storage of Products is 2 - 8DEG.C. Products may be
stored in a standard household refrigerator provided that this temperature range
can be maintained.

                                      -5-

<PAGE>

ADVERSE OUTCOMES
All reports of complaints or adverse outcomes must be required to be forwarded
immediately to LifeCell.

RETURN OF TISSUE
All expired, returned, damaged, or otherwise compromised packages or grafts must
be returned to LifeCell.

TRANSPORTATION
Products may be shipped to customers by commercial overnight courier services
without adherence to any of the product storage and handling policies and
procedures set forth in this EXHIBIT A.

                                      -6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}]]